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resumo O síndrome coronário agudo consiste num estado de sintomas físicos compatíveis com 
isquemia miocárdica aguda, podendo resultar de várias doenças arteriais coronárias: 
angina instável, enfarte agudo do miocárdio sem elevação do segmento-ST e enfarte 
agudo do miocárdio com elevação do segmento-ST. Esta doença ocorre normalmente 
devido  a  aterosclerose,  através  da  rutura  de  uma placa  aterosclerótica  instável  ou 
através de erosão endotelial. Eventualmente a ativação da cascata de coagulação e a 
adesão, ativação e agregação de plaquetas levam a trombose aguda.
A  estratificação  do  risco  em  pacientes  com  síndrome  coronário  agudo  é  muito 
importante na determinação da estratégia terapêutica adequada. Várias características 
clínicas  estão  associadas  com  um  risco  aumentado  de  um  prognóstico  adverso 
aquando de um síndrome coronário agudo, sendo tidos em conta em várias tabelas de 
previsão  de  risco.  O  principal  objetivo  deste  trabalho  é  a  determinação  de 
características clínicas associadas  com pior um prognóstico num grupo de doentes 
com síndrome coronário agudo internados na unidade de cuidados intensivos cardíacos 
do  Hospital  Infante  D.  Pedro,  no  Centro  Hospitalar  do  Baixo  Vouga,  de  forma  a 
identificar potenciais marcadores de prognóstico nestes doentes, e a determinação da 
sua  associação  com  outras  características  clínicas,  de  forma  a  determinar  a  sua 
influência na fisiologia de doentes com síndrome coronário agudo.
Levou-se a cabo um estudo prospetivo observacional em 980 doentes com síndrome 
coronário agudo internados na unidade de cuidados intensivos cardíacos do Hospital 
Infante D. Pedro, no Centro Hospitalar do Baixo Vouga, entre Janeiro de 2008 e Junho 
de 2012. A informação recolhida foi analisada usando Student's T-test, One-way Anova, 
Kruskal-Wallis test,  Pearson’s  X2 test,  Fisher's  Exact test,  Cox Proportional  Hazards 
Model e Kaplan-Meyer estimate, e incluiu informação clínica geral e informação sobre 
fatores  de  risco  cardíacos,  análise  sanguínea  geral,  marcadores  cardíacos  séricos, 
fração de ejeção ventricular esquerda, terapia de revascularização e eventos cardíacos 
prévios e posteriores.
Os resultados obtidos indicam que sexo feminino,  idade avançada,  baixa fração de 
ejeção ventricular esquerda, a presença de um evento prévio, hipertensão, dislipidémia 
e  obesidade  estão  associados  com  um  prognóstico  adverso  em  pacientes  com 
síndrome coronário agudo.

keywords atherosclerosis; acute coronary syndrome, risk factors, biomarkers, prognosis
abstract Acute coronary syndrome consists in a state of clinical symptoms compatible with acute 
myocardial ischaemia that may result from various thrombotic coronary artery diseases: 
unstable  angina,  non–ST-segment  elevation  acute  myocardial  infarction  and  ST-
segment  elevation  myocardial  infarction.  This  disease  normally  occurs  due  to 
atherosclerosis, through the rupture of an unstable atherosclerotic plaque or through 
superficial endothelial erosion. Eventually the activation of the coagulation cascade and 
platelet adhesion, activation and aggregation ends up leading to acute thrombosis.
Risk stratification in patients  with  acute coronary syndrome is very important  in  the 
determination of the proper treatment strategy. Various clinical features are known to be 
associated with an increased risk of a worse outcome in the event of an acute coronary 
syndrome and are taken into account in various risk scores. The main aim of this work 
is the determination of clinical characteristics that are associated with a worse outcome 
in a group of patients with acute coronary syndrome admitted to the Cardiac Intensive 
Care Unit of Hospital Infante D. Pedro, in Centro Hospitalar do Baixo Vouga, in order to 
identify  potential  prognostic  markers  in  these  patients,  and  the  assessment  of  the 
association of these markers with other clinical characteristics, in order to determine 
their influence in the physiology of patients with acute coronary syndrome.
A prospective observational study was conducted in 980 patients with acute coronary 
syndrome  admitted to the cardiac intensive care unit of Hospital Infante D. Pedro, in 
Centro  Hospitalar  do  Baixo   Vouga,  between  January  2008  and  June  2012.  Data 
collected  was  analysed using  Student's  T-test,  One-way Anova,  Kruskal-Wallis  test, 
Pearson’s X2 test, Fisher's Exact test, Cox Proportional Hazards Model e Kaplan-Meyer 
estimate, and included general  clinical information and information regarding cardiac 
risk factors, general blood test, serum cardiac markers, left ventricular ejection fraction, 
provided revascularization therapy and previous and posterior cardiac events
The  results  obtained  indicate  that  female  gender,  advanced  age,  anemia,  low  left 
ventricular  ejection  fraction,  the  presence  of  a  previous  event,  hypertension, 
dyslipidemia and obesity are associated with a poorer prognosis in patients with acute 
coronary syndrome.
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Prognostic markers in 980 patients with ACS hospitalized in CHBV
1 – INTRODUCTION
1.1 – Atherosclerosis
Atherosclerosis  is  a  multifactorial  disease,  in  which both  genetic  and  environmental
factors play a role, characterized by narrowing of blood vessels due to the formation of an
atheromatous  plaque.  This  is  a disease  that  may lead  to  severe  complications  like
ischaemic  cardiac  disease  and  stroke, which  constitute  a  major  cause  of  death  and
morbidity worldwide. [1]–[3]
Atherosclerosis may be considered a persistent state of chronic inflammation, due to the
interaction  of  diverse  factors,  such  as  modified  lipoproteins,  monocyte-derived
macrophages, T cells, and the normal cellular elements of the arterial wall. [4]
1.1.1 –  Overview of the atherosclerotic process
Endothelial dysfunction, resulting from various factors, triggers an inflammatory process
and  induces an  increase  in  the  permeability of  the  arterial  wall.  This  increase in  the
permeability of the arterial wall allows the passage of  low-density lipoprotein  (LDL) and
inflammatory cells from the blood to the arterial wall,  where LDL suffers oxidation and
uptake into macrophages and vascular smooth muscle cells, leading to the formation of
foam cells and to the development of an atherosclerotic lesion. [5] 
The  initial and  most  simple  atherosclerotic  lesions  are  called  fatty  streaks,  and  are
characterized by  the  accumulation  of  foam  cells  (macrophages  and  vascular  smooth
muscle cells that contain droplets of lipids) in the intima layer of the artery. These lesions
normally develop in areas where endothelial dysfunction  causes a sufficient increase in
permeability that allows the passage of LDL and inflammatory cells into the arterial wall.
[4]–[6]
The recruitment of vascular smooth muscle cells from the subendothelium and the media
induces  the  formation  of  a  fibrotic  cap,  composed  of  vascular  smooth  muscle  cells
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embedded in connective tissue.  This leads to the formation of a stable atherosclerotic
plaque, the fibrotic lesion. [5], [7]
Eventually various factors, such as vascular smooth muscle cell apoptosis and macrophage
production of  matrix  metaloproteinases  (MMPs),  end up resulting in a  thinning of the
fibrotic cap, making the plaque unstable and prone to rupture, originating a complicated
atherosclerotic lesion. [5], [7]
1.1.2 –  Pathogenesis of atherosclerosis
Endothelial lesion
There  isn't  a  clear  understanding  of  the  events  leading  to  the  development of  an
atheromatous  plaque,  although  the  most  accepted  hypothesis  to  explain  this
phenomenon  is  the  Modified  Response-to-Injury  Hypothesis,  which considers  that
endothelial  dysfunction,  resulted  from  injury,  due  to,  for  instance,  elevated  LDL,  free
radicals,  hypertension,  diabetes  mellitus  (DM),  cigarette  smoking,  increase  of  plasma
homocystein,  and infectious  microorganisms,  such  as  herpes  virus, is  the first  step  in
development of atherosclerosis. [5], [8], [9]
The endothelial surface that covers the lumen of arteries is prone to change in response
to various types of stimuli. Endothelial cells have several physiologic functions that are
important  in  the  protection  of  arteries  and  in  preventing  the  development  of
atherosclerotic  plaques.  These  functions  include,  for  example,  forming a  barrier  that
prevents  the  efflux  of  large  molecules  such  as  LDL,  into  the  subendothelial  spaces,
providing the artery with a nontrombogenic surface and releasing PGI2, heparan sulfate
and  endothelium-derived  relaxing  factor-nitric  oxide  (EDRF-NO),  which  relax smooth
muscle, increasing the diameter of the lumen, and inhibit smooth muscle cell migration
and  proliferation.  [8] Endothelium  is  also  important  for  nutrient  delivery  and  waste
removal,  and is  involved in the secretion of various substances that participate in the
processes  of  regulation  of  vascular  tone,  inflammation  and thrombosis, such as  nitric
oxide (NO),  prostaglandins,  endothelin,  and angiotensin II  (Ang II).   Thus,  a  functional
endothelium  is  fundamental  for  the  maintenance  of  an  equilibrium  between
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vasodilation/vasoconstriction and thrombosis/anticoagulation. [10]
With injury,  endothelial  cells  may become  dysfunctional. These dysfunctional  cells  are
morphologically  different  from  normal  endothelial  cells  and  present  increased
permeability and a reduction of the secretion of PGI2 and EDRF-NO, causing these cells to
have procoagulant instead of anticoagulant properties.  [5], [8] Furthermore, endothelial
dysfunction  may also  cause a  decrease  in NO and an increase  in oxidative  stress.  [9]
Endothelial  lesion also triggers an  inflammatory response that  may turn  chronic if  the
causing agent is not eliminated.  The functional differences between normal and injured
endothelium are described in table 1. [8] 
Recent studies have focused on endothelial  function,  which has been shown to be an
important indicator  in  the  determination  of the  presence  of  coronary  artery disease
(CAD). [11]
TABLE 1 – Functions of vascular endothelium in normal and injured states
Function Normal Endothelium Injured Endothelium
Permeability Tight  junctions  prevent  the
passage  of  large  molecules  into
subendothelium.
Loss  of  tight  junctions  increases
penetration of large molecules
Thrombogenicity Platelets  are  repelled  by  the
negative  surface  charge  of
endothelial cells. 
Inhibition  of  platelet  aggregation
and promotion of thrombolysis 
Function  is  converted  from
antithrombotic to prothrombotic. 
Vasomotor tone Promotion of vasodilatation Promotion of vasoconstriction
Smooth  muscle  migration  and
proliferation
Inhibition  of  smooth  muscle  cell
migration and proliferation 
Promotion  of  smooth  muscle
proliferation 
Inflammation Inflammatory  cells  fail  to  adhere
to normal endothelium.
Leukocytes  are  recruited  to  sites
of injury 
Note. Adapted from Consigny  [5]
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Inflammation
The continuous  inflammatory state  verified in atherosclerosis, particularly in regions of
disturbed laminar  flow,  such as  branch points,  leads to migration,  from the blood,  of
macrophages and lymphocytes that accumulate and multiply in the lesion. [7], [12]  This
inflammatory process may be triggered by endothelial dysfunction, structural alterations
in the luminal elastin layer and exposure of proteoglycans. [12] T-lymphocytes are found
in  various  stages  of  atherosclerotic  lesions,  along  with  a prominent  presence  of
macrophages,  which  constitutes  an  indicator  of  the  presence  of  a  nonspecific
inflammatory response. [7]
Dysfunctional endothelium expresses adhesion molecules, such as vascular cell adhesion
molecule-1  (VCAM-1),   intercellular  adhesion  molecule-1 (ICAM-1),  P-selectins and E-
selectins. VCAM-1 appears to be regulated by inflammatory stimuli, is highly expressed in
endothelial  cells  within  lesion  areas,  and a  deletion of  the  genes responsible  for  the
codification  of  E-selectins,  P-selectins  and  ICAM  results  in  a  significant  reduction  in
monocyte recruitment and atherosclerotic lesions.  [4], [6], [10] These molecules adhere
to circulating monocytes that then migrate to the vascular wall, in a process mediated by
chemoattractants such as monocyte chemoattractant protein 1 (MCP-1) and in which the
connective tissue matrix is degraded by enzymes such as MMPs. [4], [6], [10] Monocyte
migration into the cell wall may also be stimulated by oxidated LDL (oxLDL), that may both
directly attract monocytes and stimulate the secretion, by endothelial cells, of adhesion
molecules.[4]
Leukocyte recruitment  induces the secretion of various  proinflammatory molecules,  like
interleukines  (IL),  chemokynes,  cytokines  and growth factors,  such as  IL-1,  IL-6,  IL-18,
tumor necrosis  factor-α (TNF-α),  tumor necrosis  factor-β  (TNF-β),  macrophage colony-
stimulating  factor  (M-CSF),  MCP-1,  and  soluble  CD40  ligand (sCD-40L), that  stimulate
smooth muscle cells and endothelial cells and are associated with the development of the
atherosclerotic plaque.  [6],  [10] Platelet-derivered growth factor (PDGF) is secreted by
platelets, considered key cell  types in the development of atherosclerosis, and also by
macrophages and endothelial cells and is involved in the migration of smooth muscle cells
to the intimal region of arteries and in smooth muscle proliferation. [7] M-CSF, responsible
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for  the differentiation and proliferation  of  monocytes,  is  also found in  atherosclerotic
lesions, as well as sCD-40L, expressed by macrophages, lymphocytes, endothelial cells and
smooth  muscle  cells,  important  for  leukocyte  adhesion,  matrix  degeneration  and
cytokine-induced inflammation. [7], [10]
Lipid  m  etabolism  
Triglycerides  and  lipoproteins  have  an  important  role  in  the  development  of  the
atherosclerotic  lesion,  with high levels  of  triglycerides and LDL and low levels  of  high
density  lipoprotein  (HDL)  being  associated  with  a  higher  risk  of  development  of
atherosclerosis  and  an increase  in  blood  thrombogenicity.  [1],  [2] Lipids  were  once
considered initiating agents of the atherosclerotic process, but now it is believed that lipid
accumulation, characteristic of atherosclerosis  and fundamental  in the development of
the atheromatous  plaque,   occurs  in  response to changes  in  endothelial  function.  [6]
Triglyceride concentration is usually high in DM specially in the insulin resistent type, and
excess insulin promotes glycation of the lipoproteins, which has a predominant role in the
formation of atheroma. [2]
Lipid accumulation most probably results from the passage of LDL from the blood to the
vessel wall.  Once in the medial region, LDL  may be oxidated, as a result of free radicals
and the action leukocytes, and suffer uptake by macrophages and monocytes.  The high
atherogenic capacity of oxLDL results from the fact that macrophages and monocytes may
only bind to oxLDL,  as the scavenger receptors, through which they bind to oxLDL, only
recognize LDL after it suffers oxidation.  [6] The  oxLDL uptake  by  macrophages  results in
alterations  in  these  cells,  that  become  foam  cells,  less  mobile,  which causes the
accumulation  of  these  cells  in  the  intima.  Furthermore,  oxLDL constitutes  a  cause  of
endothelial  lesion  and  stimulates  the  expression  of  proinflammatory  molecules.  The
proatherogenic effects of oxLDL are described in table 2. [6], [9], [13] 
Very low-density lipoprotein (VLDL) is also  known to play a role in atherogenesis and is
associated  with  inflammatory  effects,  inducing  the  expression  of  ICAM-1,  VCAM-1,
nuclear factor-κB (NF-κB),  and other proinflammatory molecules, such as TNF- α. [9]
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Table 2 – Mechanisms of the proatherogenic effects of oxLDL components 
oxLDL Components(s) Effect  Mechanism
Lyso  phosphatidyl  choline;  oxidized
phospholipids
Increased monocyte adhesion Expression  of  adhesion
molecules on endothelial cells
Lyso  phosphatidyl  choline;  oxidized
phospholipids
Increased  monocyte  and  T  cell
chemotaxis
Stimulation  of  chemokine
production 
9-hydroxyeicosatetraenoic acid Increased CD 36 expression Activation of PPARУ
Modified  apo  B  and  oxidized
phospholipids
Increased foam cell formation Enhanced uptake of oxLDL 
Lyso;  phosphatidyl  choline,  oxidized
phospholipids
Induction  of  proinflammatory
genes
Activation of NF-kB, AP-1, and
cAMP
Oxidized lipids and apo B adducts Cellular  and  humoral  immune
response
Neoepitope formation
lyso phosphatidyl choline, cholesterol,
oxysterols
Increased apoptosis and necrosis Activation of programmed cell
death.  Loss  of  membrane
integrity
Oxidized lipids Enhanced procoagulant activity Induction  of  tissue  factor,
increased platelet aggregation
Note.  PPARУ:  Peroxisome proliferator  activated  receptor  у;  oxLDL:  oxidated  LDL;  NF-kB: nuclear  factor-κB;  AP-1:  activator
protein 1; cAMP: Cyclic adenosine monophosphate 
Adapted from Glass et al. [4]
Smooth muscle  cell proliferation  
Accumulation and proliferation of vascular smooth muscle cells in the arterial intima  is
also  a  key  feature of  atherosclerosis.  [14],  [15] In  the  early  development  of  the
atheromatous  plaque,  vascular  smooth  muscle  cells  play  an  important  role  in  the
production of pro-inflammatory mediators such as  MCP-1 and  VCAM-1. In a later state,
these cells contribute to the formation of a fibrous cap and stabilization of the plaque.
[15]
During vascular formation, there is a reduction in the secretion of extracellular matrix
proteins  and an  increase  in  the  production  of  intracellular  myofilament,  and  cells  go
through a phenotypic change. Cells undergo a transition from an active synthetic state, in
which they express genes for a number of growth-regulatory molecules and cytokines, to
a  quiescent contractile state,  that allows the cells to  contract and  dilate in response to
agents that  cause vasoconstriction or vasodilation, such as catecholamines, leukotrienes
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and NO, regulating the diameter of blood vessels and blood pressure. [13], [16]
In atherosclerosis  injured vascular smooth muscle cells are stimulated, for instance, by
growth factors and chemokines, produced by various cell types, such as endothelial cells,
platelets and inflammatory cells. [10],  [13] This  results  in  phenotypic  modifications in
vascular smooth muscle cells, that  suffer again a  change into an  active synthetic state,
migrate to the intima, proliferate and segregate matrix proteins and enzymes. [10], [13] 
Vascular smooth muscle cells are important in the secretion of various components of the
extracellular  matrix  of  the  atherosclerotic  plaque,  such  as  glycosaminoglycans,
proteoglycans,  collagen,  elastin,  fibronectin,  laminin,  vitronectin,  and thrombospondin,
inducing the formation of a mature fibrofatty atheroma. [10], [13]
Ultimately,  smooth muscle is also involved in plaque rupture. Vascular smooth muscle
cells  present  in  atherosclerotic  plaques  are  more  sensitive  to  apoptosis,  leading  to  a
thinning of the plaque's fibrous cap and, eventually, plaque rupture. [13]
Renin-angiotensin system  and oxidative stress  
Renin-angiotensin system (RAS) plays an important role in the atherosclerotic  process,
mainly through AngII and reactive oxygen species (ROS).  Furthermore, RAS is associated
with the development and proliferation of bone marrow derived cells, that are thought to
have a contribution in the pathogenesis of atherosclerosis. [17]
AngII has vasoconstrictive properties, due to the stimulation, in vascular smooth muscle
cells, of the activity of phospholipase C, resulting in an increase in the intracellular levels
of calcium and  in smooth muscle  contraction and hypertrophy.  AngII also  plays a major
role  in  atherosclerosis,  with  its  inhibition  being  associated  with  a  decrease in  the
progression of atherosclerosis and in the number of cardiovascular events. [8], [18] 
AngII is associated with the up-regulation of various adhesion molecules, chemokines and
cytokines  such  as  VCAM-1,  ICAM-1  and  MCP-1,  known  to  be  involved  in  the
atherosclerotic process, inducing endothelial dysfunction and the uptake and oxidation of
LDL.  [17], [19] The increase in the expression of adhesion molecules promoted by AngII
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makes the endothelium more prone to infiltration by inflammatory cells and facilitates the
characteristic  chronic  inflammatory process.  [19]  AngII  also promotes  platelet
aggregation through a decrease in the anticoagulant effect of NO and an increase in the
expression  of  plasminogen  activating  inhibitor-1  (PAI-1).  In  advanced  lesions  AngII
stimulates the expression of MMPs, leading to the destabilization of the plaque and may
also  alter  vascular  smooth  muscle  cell  function,  as  it  is  capable  of  inducing cellular
hypertrophy and extracellular matrix production. [2], [9], [17]
Furthermore,  AngII promotes the formation of ROS,  which is also a major factor in the
development of atherosclerosis,  in macrophages, endothelial cells and vascular smooth
muscle cells, both as  a result of the stimulation of the expression of cytokines such as
TNF-α, IL-1, IL-6 and PDGF, that induces extracellular production of ROS, and by the direct
stimulation of the activity of the membrane-bound NADH/NADPH oxidase, responsible for
the intracellular production of ROS. [2]
ROS is involved in the modulation of vascular tonus and activation of various molecules in
neutrophils  and  polymorphonuclear  leukocytes,  such  as  NF-κB,  p38  mitogen-activated
protein kinase (MAPK), c-Jun N-terminal kinases (JNKs) Akt kinases, janus kinase (JAK) and
extracellular  signal-regulated  protein  kinases (ERKs),  inducing the activation of signaling
pathways important in the events that result in the development of atherosclerosis. ERKs,
for instance, are mediators of cell proliferation, Akt kinases are associated antiapoptotic
signaling,  JNKs and p38 MAPK are important in the process of apoptosis and p38 MAPK is
thought to lead to the upregulation of ICAM-1 and endothelial dysfunction. [2], [19]  
ROS is also responsible for interfering in the growth, apoptosis and survival of endothelial
and vascular smooth muscle cells,  influencing the extent of the  response of these cell
types to stimulation by growth factors [2]
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Plaque rupture  and thrombosis  
Plaque rupture is a major concern in atherosclerosis, as it induces platelet activation and
thrombosis. This results in an impairment of the blood supply to the heart that may have
serious consequences,  with plaque rupture being associated to as much as 50 % of the
cases of acute coronary syndrome (ACS). [8]
Vulnerable plaques, more prone to rupture, often present a large lipid core and a thin
fibrous  cap,  as  a  result  of  the  action  of  MMPs  and  other  substances  secreted  by
macrophages  stimulated  by  activated  T  cells,  that  degrade  collagen  and  extracellular
matrix.[8], [10] 
The apoptosis of vascular smooth muscle cells is also a prominent factor in the events
leading to plaque rupture, as these cells are responsible for the  secretion of important
components of  the fibrous  cap.  [13],  [15] In the normal  artery there are low level  of
mitotic and apoptotic activity. In atherosclerosis, however, various factors seem to modify
the  existent  equilibrium,  making vascular  smooth  muscle  cells  more  sensitive  to
proapoptotic  stimuli.  This  could explain  why rupture  occurs  particularly  at  the plaque
shoulders,  which  often  exhibit  apoptotic  vascular  smooth  muscle  cells  and  a  more
prominent presence of inflammatory cells.[13]
With plaque rupture subendothelial collagen, the lipid core and procoagulants become in
contact with the circulating blood. This induces the activation of the coagulation cascade
and  the adhesion of platelets to the vessel  wall,  that  begin to accumulate and recruit
additional platelets,  inducing the formation of a thrombus and, eventually, occlusion of
the vase. [8], [10]
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1.2 – Acute coronary syndrome
ACS may be defined as a state of  clinical  symptoms compatible with acute myocardial
ischaemia  and  results from  various thrombotic  coronary  artery  diseases,  that  occur
normally due  to  atherosclerotic  plaque  rupture  or  superficial  endothelial  erosion:
unstable angina (UA), non–ST-segment elevation acute myocardial  infarction (NSTEMI),
and ST-segment elevation myocardial infarction (STEMI), with UA and NSTEMI normally
resulting from a  partially occluded artery and STEMI from a fully occluded artery.  [20]–
[23]
1.2.1 – Epidemiology
Cardiovascular disease (CVD) in one of leading causes of mortality and morbidity in the
world and ACS is one of the most common initial manifestations of CVD, having reached
pandemic levels in developed countries. [23]–[25] 
In  the  last  couple  of  years  there  has  been  a  reduction  in  the  mortality  rate  due  to
ischaemic heart disease, specially in developed countries, but, nonetheless, this disease is
still responsible for approximately one third of all deaths in persons older than 35 years of
age. It is also estimated that CVD causes approximately 4 million deaths in Europe every
year, representing 47% of all deaths, that ACS has an annual incidence between 1/80 and
1/170 of the population in Europe per year  and that each year in the US approximately
1,360,000 patients are admitted due to ACS. [26]–[28]
1.2.2 – Pathophysiology
The most common cause of ACS is atherosclerosis, normally through the rupture of an
unstable atherosclerotic lesion or through superficial endothelial erosion. This causes the
activation of the coagulation cascade and platelet adhesion, activation and aggregation,
causing, eventually, acute thrombosis. [22], [27]
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The thrombotic  lesion may develop through two processes. One of them is endothelial
erosion,  a  process  in  which  endothelial  denudation  in  the  plaque,  probably  due  to
endothelial cell death and apoptosis, due tho the action of macrophages, exposes larges
areas of the subendothelial connective tissue. The other is plaque disruption, in which the
rupture of the plaque's fibrotic cap exposes the underlying subendothelial matrix, rich in
tissue factor,  collagen and crystalline  surfaces,  thrombogenic  elements  that  accelerate
coagulation. [29], [30]
The thrombus normally develops in stages. Initially the thrombus starts developing within
the  lipid  core  and is  essentially  composed of  platelets.  The  thrombus  then  begins to
protrude  to  the  lumen  and  acquires  a  more  prominent  fibrotic  content  and  may
eventually continue to grow until it occludes the artery. [29]
The complete occlusion of a coronary artery leads, eventually, to myocardial infarction, as
a result of severe ischaemia,  due to a reduction of myocardial oxygen supply. Ischaemia
progresses normally from the subendocardium to the subepicardium  and the  extent of
the infarction will depend on the location, severity, and duration of the ischaemic event
and on the presence, or not, of collateral circulation. [27], [30]
Collateral circulation plays a very important role in preventing myocardial infarction.  In
UA, for instance, it is very common for patients to present a completely occluded artery
but, due to the presence of collateral circulation, these patients end up not developing
myocardial  infarction.  In  STEMI,   on the other hand,  patients  normally  also present a
completely occluded artery, but with no collateral circulation. [27]
1.2.3 – Clinical presentation
In the case of UA, chest pain, often described by the patients as a burning sensation is the
most common symptom and may also be felt in the arm, neck, jaw, inferior teeth, back or
epigastrum.   [21], [27], [31] Stable angina  in normally characterized as  as deep chest or
arm  pain  that  is  exacerbated  by  activity  or  emotional  stress  and  relieved  by  rest or
nitroglycerin,  whereas  UA is  characterized by pain that  occurs at rest  and lasts typically
less  than  20  minutes.   [20],  [22],  [27] In  certain  situations,  patients  present  atypical
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symptoms, more common in diabetic patients  (10%),  women and elderly patients, that
normally  lead  to  a  delayed  diagnosis.  These  include,  for  instance,  dyspnea,  fatigue,
lethargy,  diaphoresis, indigestion  and anxiety.  Normally, in UA, blood levels of specific
myocardial biomarkers are not elevated. [20]–[22], [31], [32]
In acute myocardial infarction chest discomfort  that lasts more than 20 minutes is the
most common symptom, being normally described as “pressure”, “dull”, “squeezing” or
“aching”. More commonly the discomfort is in the center of the chest and may also be felt
in the  left  arm,  neck,  right  arm,  epigastrium,  jaw,  teeth  or  back.  In  NSTEMI  pain  is
normally more intense and lasts for a longer period of time  and in STEMI pain is more
waning and waxing.  Associated symptoms include dyspnea, nausea,  palpitations and a
sense of impending doom. Normally, in acute mycardial infarction, blood levels of specific
myocardial biomarkers are elevated and for the dyagnosis of acute myocardial infarction
at least two of three features must be present: pain, electrocardiographic alterations and
positive myocardial biomarkers. [31]
Finally,  ischaemia  may also  occur  without  any  specific  signs  or  symptoms.  This
phenomenon is called silent ischaemia and is more common in patients with DM, women,
older adults, and those with a history of congestive heart failure (CHF). [20]
1.2.4 – Diagnosis 
Physical examination
In patients with chest pain and other symptoms suggestive of ACS physical examination
should  include  chest  examination,  auscultation  and  measure  of  heart  rate  and  blood
pressure. This evaluation is important to exclude possible non cardiac causes of chest pain
and  non  ischaemic  cardiac  disorders,  such  as  pericarditis  or  valvular  disease  and  to
determine the potential existence of haemodynamic instability or ventricular dysfunction.
[27], [30]
Occasionally patients do not present any abnormalities at physical examination. However,
when the area of ischaemia is larger and, consequently, the prognosis is worse, patients
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may present cyanosis, respiratory distress and diaphoresis.  [21], [22] 
Heart  rate  should  be evaluated  for  the  detection  of  arrhythmia,  heart  block  or  sinus
tachycardia,  what is crucial before the administration of  β-blockers. Blood pressure  may
also be normal, elevated due to, for instance, hypertension,  sympathetic stimulation, or
anxiety,  or  decreased,  due to,  for  instance,  pump failure  or inadequate preload,  with
extremes  of  blood  pressure  being  associated  with  poor  diagnosis. The  assessment  of
blood  pressure  is  very  important,  as severe  hypertension  is  a  contraindication  to
fibrinolytic treatment and should be treated emergently. 
Cardiac auscultation should target the detection of complications of ACS and the presence
of  comorbidities.  The  first  and  second  heart  sounds  are  often  reducted  due  to  poor
myocardial contractility and patients may also present a third or fourth heart sound, in the
case of heart failure due to large infarctions. The presence of a pericardial friction rub may
indicate established infarction that has happened days earlier.  Signs of left heart failure
and pulmonary hypertension should be sought at physical examination.  [22], [24]
Electrocardiogram
A patient presenting with chest pain and other symptoms compatible with ACS should do
a 12-lead electrocardiogram (ECG) as soon as possible, as this exam is the fastest way of
objectively diagnosing acute myocardial infarction  and it  may help in the  differentiation
between  myocardial  ischaemia,  injury,  and  infarction  and  locate  the  affected  area.
Furthermore, the ECG may also be very helpful in risk stratification. [20], [22], [25] 
It  is,  however,  fundamental  to  have  in  consideration  that  a  normal  ECG  does  not
completely  rule  out  the  possibility  of  ACS,  that  the  traditional  12-lead  ECG does  not
directly capture right-sided or posterior regions of the heart, and that it is important to
compare the results with the results of previous ECGs, as changes in the ECG seem to be
related with an increased possibility of complications. [22], [25] 
ECG findings are very helpful in the diagnosis of ACS and certain findings may even lead to
a suspicion of a lesion of a specific blood vessel, as  described in table  3.  Some possible
findings  in  the  ECG  suggestive  of  UA  and  NSTEMI are,  for  instance,  ST-segment
University of Aveiro – Masters in Molecular Biomedicine 13
Prognostic markers in 980 patients with ACS hospitalized in CHBV
depression,  transient ST-segment elevation, T-wave inversion, or some combination of
these factors. These alterations normally resolve when ischaemia has resolved, although
T-wave inversion  may persist.  On the other hand, ST elevation on a 12-lead ECG in two
contiguous leads is indicative of STEMI, where T-wave inversion may also be present. ST-
segment  deviation  is  an  important  and  specific  measure  of  ischaemia  and  T-wave
inversion is sensitive for ischaemia but is less specific, unless it is marked. [20], [22], [33]
Table 3 – ECG findings in the diagnosis of ACS
ECG findings Lesion Sensitivity (%) Specificity (%)
ST elevation greater in lead III than in lead II. ST
depression in lead I, lead aVL or both.
Right  coronary
artery
90 71
ST  elevation  in  leads  I,  aVL,  V5,  and  V6.  ST
depression in leads V1, V2, and V3.
Left  circumflex
coronary artery
83 96
ST elevation in leads V1, V2 and V. ST-elevation
of > 2.5 mm in lead V 1, right 
bundle branch block with Q wave, or both.
Proximal  LAD
coronary artery
12 100
ST elevation in leads V1, V2 and V. ST depression
> 1mm in leads II, III and aVF.
Proximal  LAD
coronary artery
34 98
ST elevation in leads V1, V2 and V. ST depression
≤ 1mm or ST elevation in leads II, III, and aVF
Distal  LAD
coronary artery
66 73
Note. ECG: electrocardiogram; LAD: left anterior descending
Adapted from Achar et al. [21]
Serum cardiac markers
Serum  cardiac  markers  are  vital  for  the  diagnosis  and  prognosis  of  acute  myocardial
infarction and should be measured in all  patients with chest pain or  other symptoms
suggestive of ACS. These markers are also especially important in the distinction between
UA  and  myocardial  infarction,  as  markers  of  myocardial  necrosis  and  ischaemia  are
normally elevated in myocardial infarction but not in UA. [22], [25]
The  measurement  of  cardiac-specific  troponins  T  and  I  constitutes a  highly  accurate,
sensitive, and specific determination of myocardial injury and has replaced CK-MB as the
preferred marker for the detection of myocardial necrosis. Troponins have, however, some
inconveniences:  they usually do not  increase until  at  least  6  hours  after  the onset  of
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symptoms and remain elevated for a prolonged period after myocardial necrosis, what
decreases their usefulness in detecting recurrent myocardial damage. [22]
Another promising marker being studied is copeptin, the c-terminal of the vasopressin
hormone precursor.  It  is  associated  with  states  of  acute  stress  and  may  be  useful  in
combination with a marker of myocardial injury.  [24]
Other  biochemical  markers,  such  as  C-reactive  protein  CRP  and  fibrinogen  are  also
normally  elevated  in  patients  with  ischaemic  chest  pain  and  are  indicative  of  pour
prognosis CRP is a marker of inflammation and the presence of fibrinogen indicates the
activation of the coagulation cascade. [33] 
Table 4 presents a compendium of the various features that have been discussed and that
are important in the diagnosis of ACS.
Table 4 – Likelihood that signs and symptoms indicate an ACS secondary to CAD
  Feature High likelihood Intermediate
likelihood 
Low likelihood 
History 
Chest or left arm pain/discomfort 
Previously documented angina 
Known history of CAD, including MI 
Chest  or  left  arm
pain/discomfort 
Age ≥70 and male sex
DM
Probable  ischaemic
symptoms in absence of
any  intermediate
likelihood characteristics
Examination Transient MR murmur, hypotension,
diaphoresis,  pulmonary  edema,  or
rales 
Extracardiac  vascular
disease 
Chest  discomfort
reproduced by palpation
ECG New,  or  presumably  new,  transient
ST deviation or T-wave inversion in
multiple precordial leads 
Fixed Q waves 
ST depression of 0.5-1.0
mm or T-wave inversion
>1.0 mm 
T-wave  flattening  or
inversion <1 mm
Normal ECG tracing
Cardiac
markers
 Elevated cardiac TnI, TnT, or CK-MB Normal Normal
Note. ACS: acute coronary syndrome; CAD: coronary artery disease; CK-MB: muscle and brain fraction of creatine kinase; ECG:
electrocardiogram; MI: myocardial infarction; MR: mitral regurgitation; TnI: troponin I; TnT: troponin T.
Adapted from Kumar et al. [22]
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1.2.5 – Risk stratification
Clinical risk stratification
Certain clinical features are know to indicate an increased risk of a bad outcome, such as
an advanced age,  DM,  high glucose concentration, low  left  ventricular  ejection fraction
(LVEF),  extracardiac  vascular  disease,  rest  pain,  haemodynamic  instability,  pulmonary
congestion  and evidence  of  CHF  as, for  instance, a  Killip  class  II  or  higher,  mitral
regurgitant murmur or a third heart sound. [22], [34]
Electrocardiographic risk stratification
The electrocardiographic examination is also useful in the determination of the risk of an
adverse outcome. ST-segment depression or transient ST segment elevation, for instance,
are indicative of a higher risk of adverse outcome and are predictive of three vessel or left
main stem coronary disease.  On the other hand,  T wave inversion without ST segment
shift implies a modest increased risk or no increased risk at all and no abnormal findings
on  the  electrocardiographic  examination  are indicative  of  a  favorable prognosis.  The
number of leads demonstrating ST elevation is also an important risk marker in patients
with STEMI. [22], [34]
Biochemical risk stratification
Biochemical  markers  are  also  important  in  risk  stratification.  A  troponin  increase,  for
instance,  even  if  minor,  is  associated  with  an  adverse  prognosis  and predictive  of
reinfarction, with the level of risk being proportional to the degree of increase. This is also
important  for  the  selection  of  the  treatment  that  the  patient  should  undergo,  as  it
appears that patients that present a troponin elevation seem to be more responsive to
treatment with low molecular weight heparins and platelet glycoprotein IIb/IIIa receptor
inhibitors. [22], [34] Recent studies indicate that other biochemical markers, such as brain
natriuretic peptide (BNP)  fibrinogen, CRP and sCD-40L are indicators of increased risk and
may be important in the prediction of recurrent events in troponin negative patients. [34]
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The  assessment  of  multiple  biochemical  marker  is,  though,  very  important  in  the
improvement of risk stratification and patient outcomes. [22]
Echocardiographic risk stratification
Left  ventricular  systolic  function  is  very  important  in  risk  assessment,  as  well  as
hypokinesia or akinesia in segments of the left ventricle wall. Left ventricular dysfunction
or other underlying conditions such as aortic stenosis or hypertrophic cardiomyopathy are
associated with increased risk.
Angiographic risk stratifiction
Angiography  is  helpful both  in  risk  stratification  and  in  patient  management.  This
examination  allows the determination of  the presence  of  coronary artery disease,  the
assessment of its severity and whether the patient is in need of revascularization or not. 
In addiction,  this examination is also important in risk stratification,  as  multiple-vessel
disease,  complex,  long,  heavily  calcified  lesions  or  filling  defects  indicating  coronary
thrombus are associated with a higher risk of serious cardiac events.  
Table 5 presents a compendium of the various features important for the risk assessment
of patients with ACS.
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Table 5 – Short-term risk of death or nonfatal MI in patients with UA/NSTEMI
  Feature High Risk Intermediate Risk Low Risk
History 
Accelerating ischemic symptoms
in preceding 48 h 
Previous  MI,  peripheral  or
cerebrovascular  disease,  or
CABG
Character of pain Prolonged ongoing resting pain Prolonged  resolved  rest
angina
Rest angina relieved with rest
or nitroglycerin 
Nocturnal angina 
New-onset or progressive CCS
class  III  or  IV  angina  in  the
past  2  weeks  without
prolonged rest pain
Increased  angina
frequency,  severity,
or duration
Angina provoked at a
lower threshold
New-onset  angina
with onset of 2 wk to
2 mo
Examination Pulmonary edema
New or worsening MR murmur
Hypotension
Bradycardia, Tachycardia 
Age ≥75
Age ≥70 
ECG Angina at rest with transient ST-
segment changes
Bundle branch block
Sustained ventricular tachycardia
T-wave changes 
Pathologic Q waves or resting
ST-depression in multiple lead
groups
Normal               or
unchanged findings
Cardiac markers Elevated cardiac TnT, TnI, CK-MB Slightly  elevated  cardiac  TnT,
TnI, or CK-MB 
Normal 
Note: CABG: coronary artery bypass graft; CCS: Canadian Cardiovascular Society; CK-MB: muscle and brain fraction of creatine
kinase; ECG = electrocardiogram; MI: myocardial infarction; MR: mitral regurgitation; NSTEMI: non–ST-elevation myocardial
infarction; TnI: troponin I; TnT: troponin T; UA: unstable angina
Adapted from Kumar et al. [22]
1.2.6 – Risk scores
Risk assessment  uses  quantitative or qualitative measures to determine the level of risk
associated  with  a  specific  hazard.  A quantitative  risk  assessment  may be  done  using
algorithms or mathematical formulas. Risk scores, that rank-order individuals according to
the likelihood of developing a specific outcome are more complicated to use, but are also
more precise than the simple qualitative risk assessment. [35] There are different scores,
based on initial clinical history, ECG, and laboratory tests, including Platelet glycoprotein
IIb/IIIa  in  Unstable  angina:  Receptor  Suppression  Using  Integrilin  Therapy  (PURSUIT),
Thrombolysis In Myocardial  Infarction (TIMI),  Global Registry of Acute Coronary Events
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(GRACE)  and Can Rapid risk stratification of Unstable angina patients Suppress ADverse
outcomes with Early implementation of the ACC/AHA guideline (CRUSADE) [35]–[37]
PURSUIT
The PURSUIT is a risk score, developed in 2000, that predicts 30-day risk and ranges from
0 to  18.  This  score is  based on age,  sex,  worst  Canadian Cardiovascular  Society  (CCS)
angina class in the previous six weeks, heart rate, signs of heart failure and ST depression,
as described in table 6.  In this score age is the most significant predictor. The original trial
score presented a c-statistic of 0.84 for death alone and 0.67 for the composite endpoint
of death/miocardial infarction. [37], [38]
Table 6 – PURSUIT risk score
Characteristic Score
Age
50
60
70
80
8
9
11
12
Sex
Male
Female
1
0
Worst CCS class past 6 weeks
No angina/ CCS I/II
CCS III/IV
0
2
Signs of heart faillure 2
ST depression on ECG 1
Note: CCS: canadian cardiovascular society
Adapted from Backus et al. [37]
TIMI
The TIMI risk score, developed in 2000, analyzes various independent prognostic variables
and uses logistic regression,  assigning the value of 1 if the variable is present and the
value of 0 if the variable is absent. The variables utilized are age of 65 years or older, at
least  three  risk  factors  for  CAD,  prior  coronary  stenosis  of  50% or  more,  ST-segment
deviation on ECG at presentation, at least two anginal events in the previous 24h, use of
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acetylsalicylic acid in the previous seven days and elevated serum cardiac markers.   The
TIMI  score  predicts  the  risk  of  all  cause  mortality,  miocardial  infarction and  severe
recurrent ischaemia requiring urgent revascularization within 14 days after admission and
had, in the original trial, a c-statistic of 0.65. [37], [38]
GRACE
The GRACE score was developed in 2003 and analyzed 8 independent risk factors: Killip
class,   systolic  blood  pressure,  heart  rate,   age,  creatinine  level,  cardiac  arrest  at
admission, ST segment deviation on ECG and elevated cardiac enzyme levels, as described
in table 7. Each one of these elements has its own scoring, resulting in a possible score
ranging from 1 to 372.  The GRACE score had, in the original trial, a c-statistic of 0.83. [37]
Table 7 – GRACE risk score
Killip
Class
Score Sistolic b.
presure
Score Heart
Rate
Score Age Score Creatinine
Level
Score Other Score
 I
II
III
IV
0
20
39
59
<80
80-99
100-119
120-139
140-159
160-199
>200
58
53
43
34
24
10
0
<50
50-69
70-89
90-109
110-
149
150-
199
>200
0
3
9
15
24
28
46
<30
30-03
40-49
50-59
60-69
70-79
80-89
>90
0
8
25
41
58
75
91
100
0-0.39
0.40-0.79
0.80-1.19
1.20-1.59
1.60-1.99
2.00-3.99
>4
1
4
7
10
13
21
28
Cardiac
arrest at
admission
ST
deviation
Elevated
cardiac
markers
39
28
14
Note: Adapted from Backus et al. [37]
CRUSADE
The CRUSADE risk score estimates baseline risk of in-hospital major bleeding in patients
with NSTEMI and takes into account baseline hematocrit, creatinine clearance, heart rate,
gender,  signs  of  CHF  at  presentation,  prior  vascular  disease,  DM,  and  systolic  blood
pressure. [39]
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1.2.7 – Therapy
Oxygen
The routine usage of oxygen therapy in patients with uncomplicated ACS without signs of
hypoxia or heart failure is not recommended. There is not enough evidence to suggest a
benefit in patients with normal oxygen saturation levels, with some trials even indicating
the possibility of harm and, although oxygen therapy has been linked with a reduction in
the extent of ischaemic lesion in animal models and with an improvement in ST-segment
changes, it seems to not influence the mortality rate. [24], [40], [41]
Oxygen  administration is normally  recommended only when patients with ACS present
breathlessness, signs of heart failure, shock, or an arterial oxyhemoglobin saturation of
less than 90% and, in that case, oxygen should be administered at 2 to 4 L/min by nasal
cannula. [20], [28], [40], [41]
Anti-ischaemic agents
Various  anti-ischaemic  agents  are used  in  the  treatment  of  ACS,  such  as  β-blockers,
nitrates, calcium channel blockers and potassium channel activators.
β-blocking  agents  seem  to  have  a  beneficial  action  in  patients  presenting  with  ACS
without  ST-elevation.  These  agents  competitively  inhibit  the  effects  of  circulating
catecholamines and seem to  exert their beneficial function in the management of ACS
through their action on beta-1 receptors, that results in a decrease in myocardial oxygen
consumption.  [30] Studies suggest that the use of  β-blockers in the treatment of UA is
associated  with  a  13%  relative  reduction  in  risk  of  progression  to  acute  miocardial
infarction and that these agents are associated with a reduction in mortality and in the
size  of  the  ischaemic  lesion  in  patients  with  acute  myocardial  infarction.  However,  it
seems to be associated with an  increase in  the number of cases of cardiogenic shock.
[30],  [41], [42] There are some contraindications in the use of  β-blockers, such  as  left
ventricular  failure,  pulmonary  edema,  bradycardia,  hypotension  and  poor  peripheral
perfusion. [40], [43]
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Nitrates and similar drug classes exert their beneficial therapeutic effects in patients with
ACS  through  their  action  on  the  peripheral  and  coronary  circulation,  as  they  have
vasodilator properties that  cause  a decrease in myocardial preload and left ventricular
diastolic  volume,  leading  to  a  decrease  in  myocardial  oxygen  demand.  Furthermore
nitrates have  also  a  role  in  improving coronary  collateral  flow and  inhibiting platelet
aggregation. [22], [30] There aren't, however, trials that confirm their benefits in relieving
symptoms, in reducing major adverse cardiac events  or in increasing survival in younger
patients,  although   in the elderly  their  use  is associated with a reduction in mortality, 
heart failure, and left ventricular dysfunction. Therefore,  when symptoms are controlled,
intravenous  nitrates  should  be  replaced  by  alternatives  such  as  sydnonimines  or
potassium channel  activators.  [30],  [42] Some contraindications  in  the use of  nitrates
include, for instance, bradycardia or tachycardia in the absence of heart failure, or the use
of a phosphodiesterase inhibitor for erectile dysfunction within 24 or 48 hours, depending
on the therapeutic agent used. [22], [24]
Calcium channel blockers have vasodilating properties and also exert a direct effect on
atrioventricular conduction and heart rate, inhibiting the contraction of both myocardium
and  vascular  smooth  muscle.  [22],  [30] This  therapeutic  class  may be  divided  in  3
subclasses  with  distinct  pharmacological  effects that  cause  similar  levels  of  coronary
vasodilatation: dihydropyridines, benzothiazepines, and phenylalkylamines.  [30] Calcium
channel blockers seem to have an efficiency in the relieve of ACS symptoms similar to that
of β-blockers  and seem to provide symptom relief in patients already receiving nitrates
and β-blockers. Thereby, their use is recommended in patients that present persistent or
recurrent  symptoms  even  after  treatment  with  nitrates  and  β-blockers,  although  β-
blockers should always be the first choice, if they are not contraindicated, as they have
been used more broadly and have a safer profile. [22], [30], [41] Calcium channel blockers,
however,  do  not  seem to  prevent  the development of  acute  myocardial  infarction  or
reduce mortality and should not be administered to patients presenting with severe left
ventricular dysfunction or pulmonary edema. [22], [30]
Potassium  channel  activators  exhibit  both  arterial  and  venous  dilating  properties,
although they do not exhibit the same tolerance as seen with nitrates. [27], [30] The use
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of such therapeutic agents in patients with stable angina is associated with a reduction of
cardiovascular death, non-fatal  myocardial infarction and unplanned hospitalization  due
to angina, although there seems to be no significant alteration in coronary heart disease
mortality and non-fatal  myocardial infarction and no specific data  in the case of  acute
coronary syndromes.[30]
Anti  t  hrombotic therapy  
Antithrombotic therapy plays a major role in the management of ACS, as thrombosis is a
major factor in ACS. Anti-thrombotic agents include agents that inhibit thrombin, such as
unfractionated heparin or low-molecular-weight heparin, and antiplatelet agents such as
aspirin, clopidogrel, ticagrelor and GPIIb/IIIa receptor blockers. [30]
Unfractionated heparin  has  the inconvenience of  having  variable  anticoagulant  effects
and limited  effectiveness  against  platelet-rich  and  clot-bound  thrombin  but,  in  the
absence of  aspirin,  its  use  is  associated with a  lower  frequency of  refractory  angina/
myocardial infarction and death, although its use with aspirin does not seem to increase
the protective effect of aspirin alone. However, this initial protective effect is lost with the
discontinuation of therapy.  [22], [30] It should be paid close attention to the complete
blood cell count, as autoimmune heparin-induced thrombocytopenia in association with
thrombosis, although rare,  may happen with treatment with unfractionated heparin. If
this complication occurs heparin therapy should be immediately discontinued. [22]
Low-molecular-weight heparins seem to have an enhanced anti-Xa activity in relation to
anti-IIa activity and seem to be associated with a decrease in sensitivity to platelet factor
4,  having a  more predictable anticoagulant effect  and lower rates of thrombocytopenia.
Low-molecular-weight heparins do not seem to be associated with an increased beneficial
effect, in relation to placebo, when administrated in the presence of aspirin and there also
does  not seem to exist a significant difference in the efficacy of  low-molecular-weight
heparins  in  relation  to  unfractionated  heparin.  Furthermore,  although  low-molecular-
weight  heparins offer  some  practical  advantages,  such as  simplicity  of  administration,
more consistent antithrombin effects  and  lack of need  of monitoring,  they seem to be
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associated with a significantly increased risk of major bleeding. [30]
Acetylsalicylic  acid  acts  inhibiting  cyclo-oxygenase-1  and  blocking  the  formation  of
thromboxane A2, inhibiting, therefore, platelet aggregation induced via this pathway. [20],
[30] Its administration is associated with a decrease in death and MI in patients with UA
and  with  a  decrease  in  vascular  events  in  patients  with  myocardial  infarction and,
therefore,  acute treatment with aspirin is recommended in all  patients with suspected
ACS. [30], [34], [43] Continued use is also recommended, as it  is associated with a long-
term  benefit.  There  exist,  however,  certain  contraindications,  such  as  allergy  to
acetylsalicylic  acid,  active peptic  ulcer,  local  bleeding or  haemorrhagic  diatheses.  [20],
[30], [42]
Clopidogrel is an oral thienopyridine prodrug that requires activation in the liver via the
cytochrome P450 system and that irreversibly inhibits the P2Y12 adenosine diphosphate
receptor on the platelet, causing a reduction in platelet aggregation. Studies indicate that
clopidogrel  administration in patients with NSTEMI results  in a reduction in combined
event rate and mortality and that clopidogrel given 6 hours or more before elective PCI for
patients with ACS without ST elevation reduces adverse ischemic events at 28 days. [22],
[28], [41]
Ticagrelor is a non-thienopyridine drug, with a half-life of approximately 12 hours, that is a
reversible  antagonist  of  the  P2Y12  adenosine  diphosphate  receptor  on  the  platelet.
Studies have reported an improvement in overall mortality and combined event rates with
a marginal increase in bleeding the with administration of ticagrelor. [22], [28], [40]
Platelet GP IIb/IIIa  inhibitors  are  specific  inhibitors  of  platelet  aggregation that  act  by
interrupting the final common pathway of fibrinogen-mediated cross-linkage of platelets.
Several trials have shown that these inhibitors have substantial benefit for patients at high
risk and those undergoing PCI. [22]
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Fibrinolytic  t  herapy  
Fibrinolytic therapy consists in the administration of clot-busting drugs such as alteplase,
reteplase and tenecteplase,  which dissolve existing thrombi by converting plasminogen to
plasmin and degrading fibrin clots. This therapy is most effective when given within three
hours  after  symptom  onset  and  should  be  initiated  within  30  minutes  of  medical
evaluation.  There  are,  however,  certain  contraindications,  such  as  bleeding  disorder,
recent surgery or other invasive procedure, trauma, active peptic ulcer disease, use of
anticoagulants, recent ischemic stroke, uncontrolled hypertension and brain tumor.  [20],
[24] 
Coronary revascularization 
There are two options for the coronary revascularization of patients presenting with ACS:
percutaneous coronary intervention (PCI)  or  coronary artery  bypass  graft  (CABG).  The
decision to submit the patient to coronary revascularization and the choice of the most
adequate technique depends on the extent and angiographic characteristics of the lesions
present. [30]
PCI allows the mechanic stabilization of the disrupted plaque through the insertion of a
catheter,  normally through the femoral artery, into the occluded coronary artery.  [20],
[30]  Percutaneous transluminal coronary angioplasty  (PTCA) consists in the insertion of a
catheter with a balloon tip that is then inflated, allowing the opening of the artery.  [20]
Various trials attest that the mortality rate associated with this procedure is very low and
that the rate of success seems to be improved with the use of a stent, a metal device that
keeps the artery open, and administration of GPIIb/IIIa receptor inhibitors, aspirin and
heparin. [30] Some possible complications are, for instance, bleeding in the insertion site,
decreased peripheral perfusion, retroperitoneal bleeding, cardiac arrhythmia, and acute
renal failure. [20]
CABG is a technique in which  bypass grafts,  composed of other arteries and veins from
the body, are attached onto a source of blood supply, most commonly the aorta, and onto
the blocked  coronary artery in a location beyond the blockage,  providing an alternative
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route  for  blood  flow.  In  this technique  advanced   age   is   associated   with   higher 
morbidity   and   mortality,  probably  due to  increased severity of coronary artery disease 
and increased frequency of comorbid medical conditions in elderly patients.  [30],  [42] In
spite  of  this,  elderly patients  seem  to  present  improved outcomes after CABG  and,
therefore,  should not be denied CABG solely due  to their  age,  although,  in  these cases,
particular attention should be paid to  baseline functional capacity and comorbid medical 
conditions. [42]
Patients with single-vessel disease are usually treated by PCI, with CABG normally only
being a possibility in the case of,  for instance, marked angulation or  tortuosity of the
vessel. On the other hand, in the case of left main or three-vessel disease, especially if
associated left ventricular dysfunction, the choice is normally CABG if some of the lesions
may not be appropriately managed with angioplasty.  [30] However, the situation should
always be  evaluated on an individual patient basis.  For instance, in the case of patients
who  need total revascularization,  not possible with PCI, but in whom surgery poses an
extremely high risk,  the choice may be an initial percutaneous treatment of the ‘culprit’
lesion only  and in the case of  left main narrowing  associated with severe  co-morbidity,
angioplasty may be the best choice in certain cases. [30]
1.2.8 – Risk factors
Obesity
Excessive  accumulation of adipose tissue occurs when energy intake chronically exceeds
energy expenditure, resulting from, for instance, an excessive intake of fat and sugar and a
sedentary lifestyle. Obesity is a multifactorial disease in which metabolic, physiological,
environmental, genetic, behavioral, and social factors play a role. [44], [45]
Obesity is associated with increased mortality and seems to have a strong correlation with
lipoprotein levels,  LDL in particular, and insulinemia  and is a particularly important risk
factor, especially because it is normally associated with two very important known risk
factors for CVD, DM and hypertension. [44], [46], [47]
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Various studies show an increase in the number of overweight children and adolescents in
the past few decades, an increase associated with an increased risk of hypertension, lipid
abnormalities, type II diabetes, and atherosclerotic lesions. [44]
It  is,  therefore,  very  important  to  prevent  obesity  with  changes  in diet,  exercise  and
behavioral modification. It is important for this prevention to begin in the childhood, as
children who are obese are more likely to become obese adults [44] 
The waist/hip ratio and waist circumference are the most widely used measure of central
adiposity and they seem to be better predictors of CVD than measures of overall adiposity
such as the body mass index (BMI). [48]–[51]
Hypertension
Hypertension is one of the most important and common risk factors for CVD, with various
studies  indicating  that  it  increases  the  risk  of  cardiovascular  and  atherosclerotic
occurrences approximately two to three  fold,  independently of other risk factors.  [48],
[49] 
It  is  a  multifactorial  disease,  usually  asymptomatic,  one of  the factors  that  makes its
prevention and early diagnosis so important. A patient is diagnosed with hypertension
normally when  sistolic blood pressure or diastolic  blood pressure  are greater than the
95th percentile for sex, age, and height, plus 5 mmHg on 3 separate occasions. [44]
AngII and NO play an important role in the regulation of arterial blood pressure and are,
as already discussed, also thought to be major interveners in the atherosclerotic process.
Obesity  also  has  a  very  prominent  role  in  the  development  of  hypertension,  as
approximately  30%  of  children  and  adolescents  with  overweight/obesity  have
hypertension.  Smoking and alcohol  consumption also seem to increase the risk of the
development of hypertension. [44]
The best way to prevent the development of hypertension seems to be a healthy lifestyle
with weight control, moderated sodium and alcohol intake and exercise.  [44], [52]
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Diabetes  m  ellitus  
DM is a metabolic disorder  mainly characterized by elevated blood glucose levels  and
constitutes a strong risk factor  for CVD and ischaemic heart disease, as  cardiovascular
complications are the leading cause of morbidity and mortality in patients with DM, with
about  75–80% of  adult  diabetic  patients  dying  of  CVD.  DM seems to  have  a  greater
associated risk of CVD in women, with a three to seven-fold increased risk, than in men,
where it is associated with a two to three-fold increased risk. [48], [49], [53], [54] 
As this is a disease that often coexists with other significant risk factors such as obesity,
dyslipidemia,  hypertension,  and  hyperuricaemia  patients  with  DM  are  particularly
predisposed  to  atherosclerotic  disease  and  even  modest  elevations  in  blood  glucose,
without a diagnosis of DM, have been linked to an increased risk for development of CAD.
[48], [55]
DM is associated with an increased mortality rate from myocardial infarction in women,
both  when comparing  to  women without  DM and  when comparing  to  men,  with  or
without DM. It  is  also associated with alterations in the lipid profile,  such as elevated
triglycerides and low HLD and VLDL levels, that are predictive of coronary artery disease
mortality in diabetic women but not in non diabetic women or in men.  [49]
Various studies have shown that DM is also associated with a worse prognosis in patients
with ACS, as DM increases the susceptibility of the heart to ischaemia/reperfusion injury.
[56]
Dyslipidemia
Elevated levels of total cholesterol and LDL are associated with an increased risk of ACS
both in men and women. It is especially important a control of LDL in postmenopausal
women, as menopause is associated with a decline in the levels of estrogen, that result in
a  decrease  in  the  activity  of  LDL  receptors  and,  therefore,  in  an  increase  in  LDL
concentration.  A reduction of  a  high cholesterol  level  in  patients with  coronary heart
disease is thought to reduce major coronary events by 34%. [49]
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Low  levels  of  HDL  are  associated  with  an  increased  risk  of  coronary  heart  disease,
especially  in  women,  as  it  is  thought  that  low  levels  of  HDL  are  more  predictive  of
coronary artery disease in women than in men.  Recent studies show a decrease in HDL
levels in women after menopause what, in combination with an increase in LDL levels,
may  explain  the  increase  in  coronary  risk  in  postmenopausal  women.  Initially  it  was
thought  that  low  HDL levels,  by themselves,   in the absence of  high levels  of  LDL or
triglycerides, did  not result in an increased risk of CVD, but  recent studies indicate that
isolated low HDL levels constitute a significant risk factor. [49]
Elevated triglycerides are also another important risk factor for CVD, although their role as
an independent risk factor for CVD is not clear, due to their interactions with other lipid
factors,  with  certain studies indicating that the  measurement of  serum triglycerides for
the  estimation  of cardiovascular  risk  has no  advantage  over  the  measurement  of
cholesterol  alone.  [48],  [49],  [57] Certain  meta-analysis  studies,  however,  indicate  a
statistically significant increase in cardiovascular risk associated with a 1-mmol/l increase
in triglycerides of 14% in men and 37% in women. [49], [57] 
Lifestyle  interventions  such  as  reduction  in  total  calories,  weight  loss and  increased
physical  activity  are  important  in  the  management  of dyslipidemia,  although
pharmacological therapy may also be necessary. [58]
Homocysteine
Elevated levels of total plasma homocysteine seem to be associated with an increased risk
of CVD both in women and in men, with meta-analysis indicating an odds-ration of 1.6 for
men and 1.8 for women, in association with a 5-mmol/l increment. [48], [49], [57]
Plasma homocysteine levels seem to rise with age and be significantly higher in men than
in women, possibly due to an increased body mass in men and to a lowering effect of
estrogen in women, what may explain the increased levels in postmenopausal women, in
relation to premenopausal women and even to men of the same age. [49]
The role of homocysteine as a risk factor may be explained by the fact that it is associated
with  endothelial  dysfunction  and  injury  and  with  vascular  smooth-muscle  cell
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proliferation. It is also responsible for increasing thromboxane A2 formation and platelet
aggregation and also has procoagulant effects. A potential increase in the levels of plasma
homocysteine my be due to genetic, nutritional and environmental factors. [57], [59]
Fibrinogen
Various studies indicate a significant correlation between fibrinogen levels and CVD, with
meta-analysis  indicating  that  high  fibrinogen  levels  have  an  odds  ratio  of  2.3  for
cardiovascular events. [48], [49], [57] 
Fibrinogen levels seem to be higher in women than in men, especially in postmenopausal
women, and seem to rise with smoking, age obesity  and physical inactivity.  [49], [57] In
patients  with  established coronary  disease,  the  grade  of  increase  in  fibrinogen  levels
seems to be associated with the severity of the lesions and, in patients with UA, high
fibrinogen levels are associated with a higher risk of death or myocardial infarction. [57] 
Fibrinogen is associated with an increased risk of CVD because it seems to have mitogenic
and angiogenic properties, due to its role in the coagulation cascade, in the stimulation of
vascular smooth muscle cell migration and proliferation and in the promotion of platelet
aggregation. [57]
Familiar history
Coronary heart disease seems to have a strong hereditary component. Therefore, positive
familiar history  of  premature  coronary  heart  disease  is  a  known  genetic  risk  factor,
present in the majority of cases of premature-onset, that has been added to various risk
prediction models. However, the analysis of familiar history as a risk factor for CVD is not
always easy,  as the definition and identification of a positive familiar history  of CVD is
difficult and because it  is  normally associated with other risk factors,  what makes the
assessment of the separate impacts of genetic and environmental factors difficult.  [49],
[59]–[61]
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Family history of  coronary heart disease seems to increase the probability of premature
onset in women and men, with certain studies even indicating that the presence a familiar
history of CVD could double the patient's risk of myocardial infarction. [49], [59]
At this point, however, the practical implications of the identification of families at risk are
not clear, although, in the future, with the development of genetic  research, it may be
possible to determine different subtypes in the familial risk  and specific therapy.  [49]
Smoking  and  alcohol  consumption  
In smokers, the risk of CVD seems to be proportional to the number of cigarettes smoked
and is apparently greater for women than men.  It is also important to notice that there
seems to be a substantial decrease in coronary heart disease mortality  in former smokers
compared with continuing smokers. [48], [62]
Smoking seems to be associated with oxidative  stress,  lipid oxidation,  endothelial  cell
dysfunction  and  foam  cell  proliferation,  as  well  as  with  an  increase  in  inflammatory
markers, what suggests that it is involved in the inflammatory process characteristic of
atherosclerosis. [63]
Moderate alcohol intake seems to be protective for CVD, with a reduction of 20-40% in
mortality and morbidity due to coronary heart disease, whereas more than two drinks a
day  seems  to  be  associated  with  increased  mortality.  [45],  [48],  [64],  [65] The  risk
reduction by moderate alcohol consumption may be explained by an increase HLD but is
also related to levels of fibrinogen and glycated hemoglobin. [64]
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1.3 – Biomarkers
1.3.1 – Inflammatory markers
CRP
CRP is the most important  and the best studied  inflammatory biomarker for  ACS.  It  is
synthesized essentially in the liver, although it may also be produced by other cells such as
adipocytes, and is normally present in low, stable levels of less than 1 mg/L in the absence
of an acute inflammatory stimulus. [66], [67]
CRP is involved in the inflammatory process by binding to endogenous and exogenous
ligands,  such  as  modified  lipoproteins and  apoptotic  cells,  thereby  protecting against
infection and tissue injury, and activating the complement cascade. [67]
It is thought that CRP has an important role in plaque formation and development, as it is
normally associated with the presence of foam cells. Studies have demonstrated that CRP
is associated with a decrease in endothelial NO synthase and an increase in endothelin-1
secretion, therefore leading to an increase in the expression of adhesion molecules such
as ICAM-1,VCAM-1, E-selectin and P-selectin. CRP is also associated with and increase in
LDL uptake and MCP-1 secretion, and with the induction of vascular smooth muscle cell
apoptosis. These alterations are, as already discussed, key elements in the atherosclerotic
process. [67], [68]
In spite of the doubts regarding the functional role of CRP in the pathogenesis of ACS, it is
clear that it  is a useful,  sensitive  biomarker in  the detection of  ACS,  as a marker of a
proinflammatory state and plaque instability. In myocardial infarction there is normally an
accentuated rise  in  circulating  CRP  levels,  directly  correlated  with  the  extension  of
myocardial injury, and an accumulation of CRP in the damaged myocardium, where it has
a role in the opsonization of necrotic tissue. [67]–[70] CRP has the advantages of having
relatively stable  levels and  a large availability of assays,  although it must be taken into
account that this is not a specific biomarker, as it may also be elevated in result from other
inflammatory processes not associated with ACS.  [67]
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Adhesion  m  olecules  
As  previously  discussed,  various  adhesion  molecules,  including  P-selectin,  E-selectin,
VCAM-1  and  ICAM-1,  are  upregulated  as  a  result  of  the  endothelial  cell  activation
characteristic  of  the atherosclerotic  process.  These adhesion molecules  are  associated
with  leukocyte  recruitment  and  migration  into  the  vessel  wall  and  are,  therefore,
fundamental in the development of atherosclerotic plaques.  Thus, these are important
biomarkers  for  ACS,  that  are  directly  associated  with  the  biological  mechanisms  that
promote arterial thrombus and subsequent cardiovascular events. [67], [70]
VCAM-1  is  involved  in  platelet  activation  and  in  the  balance  of  fibrin  formation  and
fibrinolysis, and seems to be associated with death and recurrent nonfatal ACS. [70]
Inflammatory cytokines and chemokines
Inflammatory cytokines and chemokines are also potential biomarkers for ACS, as they are
particularly  important  in  the  inflammatory  response  verified  in  atherosclerosis.  Foam
cells,  for  instance,  secrete  a  variety  of  cytokines,  such  as  IL-1,   Il-6  and  TNF-α,  and
chemokines,  such  as  MCP-1.  This  leads  to  the  secretion,  from  endothelial  cells,  of
adhesion molecules that promote leucocyte recruitment to the intima, perpetuating the
inflammatory response.[67]
TNF-α IL-1, IL-6, and IL-18 are considered to be produced by nucleated cells in the heart in
response to a precipitating event, such as ischemic cardiac injury, due to innate stress
responses. The expression of these cytokines seems to lead to deleterious effects on left
ventricular function and acceleration of the progression of heart failure, due to myocyte
apoptosis  and  necrosis,  with  IL-6  being  associated  with  hypertrophic  response  in
myocytes and TNF-α with left ventricular hypertrophy, presumably due to activation of
matrix metalloproteinases. [71]
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1.3.2 –  Markers of plaque rupture
s  CD  -  40L  
CD-40  is  a  cell  surface  receptor  expressed  in various  cell  types,  including  B-cells,
macrophages, endothelial cells, vascular smooth muscle cells and platelets.  CD-40 ligand
(CD-40L)  is  a  transmembrane protein  structurally  related to  TNF-α  that  was originally
identified on CD4+ T cells, but is also found on activated platelets. [72]–[74]
With platelet activation CD-40L is recruited and clived into sCD-40L which binds to CD40
receptor in the endothelial membrane. Various studies suggest that interactions between
CD-40 and CD-40L are associated with atherogenic and thrombotic mechanisms, inducing
various  inflammatory  responses,  matrix  degradation, tissue  factor  expression  on
macrophages and  a decrease in thrombomodulin expression, leading to a procoagulant
and prothrombotic state. [72]–[74]
sCD-40L is, therefore, a marker of platelet activation and, thus,  also  a marker  of plaque
rupture  and  inflammatory  thrombotic  activity,  with  elevated  levels  being  reported  in
patients with both UA and acute myocardial infarction. [72]–[74]
Placental  g  rowth  f actor  
PlGF was originally discovered in the placenta, but is also present in a range of other
tissues including the heart. It is a functional cytokine, associated with angiogenesis and
atherogenic migration of monocytes/macrophages into the arterial wall. [75]
Recent  studies  have  shown  that PlGF  is  important  in  both  early  and  advanced
atherosclerotic lesions,  possibly being an instigator of plaque instability during the acute
phase of  ACS  and is,  therefore,  a  potentially  useful  biomarker  associated with plaque
instability and rupture.  Since PlGF is associated with the recruitment of machophages,
important in the removal of necrotic tissue, it is thought that PlGF may be released into
vulnerable plaques from damaged cardiomyocites. [76], [77]
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1.3.3 – Markers of thrombosis
Plaminogen  a  ctivator  i nhibitor-1  
PAI-1 is a serine protease, synthesized in platelets endothelium and adipose tissue, that is
important in the blockage of he conversion of plasminogen to plasmin and, therefore, in
the inhibition of  fibrinolysis.  PAI-1 acts  binding to tissue plasminogen activator  (t-PA),
forming a stable complex, that is then cleared from blood circulation in the liver. [78]
Studies have shown that the occurrence of myocardial infarction is sometimes preceded
by a rise in the circulating level of PAI-1 and ACS patients usually present elevated plasma
levels of PAI-1, in conformity with the prothrombotic state verified after plaque rupture. In
patients with acute ST-elevated myocardial infarction this elevation of the plasma levels of
PAI-1 is strongly associated with the risk of mortality during a 1 month period. [79]
It is however, important to have into account that the measurement of plasma PAI-1 levels
does not exactly reflect the local release of PAI-1, from platelet granules, that prevents
thrombolysis  during  thrombus formation.  Studies  indicate  that,  in  patients  with acute
myocardial infaction, platelet-derived PAI-1 concentration is much higher than plasma PAI-
1  and,  therefore,  the  measurement  of  plasma  PAI-1  may  not  accurately  reflect  the
influence of PAI-1 in the formation and stability of an arterial thrombus. [80]
v  on Willebrand factor  
von Willebrand factor (vWf) is a glicoprotein, produced almost exclusively by endothelial
cells,   that is  involved in platelet aggregation and adhesion and  presents an increased
release with endothelial damage, what suggests an association with thrombogenesis and
atherosclerotic vascular disease. [81]–[83]
vWf is  extremely important  in  thrombus formation,  with its  deficiency  causing severe
hemophilia.  In early  stages  of  thrombus  formation,  with  the  exposition  of  the
subendothelial matrix of the blood vessel,  vWf binds to matrix components and platelets
adhere  to  vWf  through  glycoprotein  IIb  r  IIIa  receptors,  which promots platelet
aggregation and the formation of a platelet plug.  vWf also acts as a carrier protein for
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factor  VIII  and  when  vWf  binds  to  collagen  in  the  subendothelial  connective  tissue
conformational  alterations  occur  in  vWf  that  cause  the release  of  factor  VIII,  also
important in the fibrin clot formation.  [81]–[83]
High concentrations of vWf may, therefore, be an indirect indicator of atherosclerosis and
of thrombosis,   with  increased  concentrations  being  found  in  patients  with  previous
myocardial  infarction  and,  in  the  case  of  UA,  correlating  with  the  clinical  severity  of
angina. [81]
1.3.4 – Markers of ischaemia
Isch  a  emia  m  odified  a  lbumin  
Ischaemia  modified  albumin  (IMA)  is  produced  during  myocardial  ischaemia,  due  to
structural  changes  in  the  N-terminal of  serum  albumin  that  make the  N-terminal
aminoacids unable to bind to transition metals, potentially as a result of the release of
ROS during ischaemia. [84]–[86]
IMA is, therefore, a sensitive marker for the diagnosis of myocardial ischaemia and has a
very  important  role in  the detection  of  ACS  in  patients  with  chest  pain,  with  studies
indicating that IMA has a greater sensitivity in the diagnosis of ACS than ECG and cTnT,
used alone or combined. [84], [87]
Brain  n  atriuretic peptide  
BNP is primarily secreted by the ventricles, in a response to left ventricular stretching or
wall tension.  It constitutes a homeostatic signal  important in  maintaining a stable blood
pressure and plasma volume and in the prevention of excessive salt and water retention,
exerting  various  functions,  including  natriuresis,  vasodilatation  and  inhibition  of  RAS–
aldosterone and sympathetic nervous system. [88], [89]
BNP levels  constitute,  therefore, a simple and objective way of  assessment of  cardiac
function and a biomarker of myocardial injury. [88]
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Choline
Elevated levels of whole-blood choline (WBCho), free plasma choline (PCho) and serum
choline  (SCho)  are  thought  to  be  markers  of  plaque  destabilization  and  ischaemia  in
patients with ACS, as studies have showed choline to be released together with troponin I
from the myocardium. [90]
1.3.5 – Prognostic markers
Serum  u  ric  a  cid  
Serum uric acid is the main end product of  the  metabolism of purins and an important
prognostic biomarker associated with poor outcome, both in the general population and
in patients with ACS,  with studies indicating a strong relation between serum uric acid
levels at the time of admission and in-hospital and short-term mortality in male patients
with STEMI. [91]–[93]
An increased concentration of serum uric acid usually reflects an increase in the xanthine
oxidase pathway activity. This pathway constitutes an important source of ROS,  that has
an  important  role  in  CVD.  ROS,  as  previously  discussed,  is associated  with  impaired
regulation of vascular tone, due to deficient NO production and endothelial dysfunction.
Therefore, elevated levels of serum  uric acid are a  useful clinical indicator of  oxidative
stress and may be indirectly associated with endothelial dysfunction. [91], [92] 
Patients  usually  present  increased  levels  of  uric  acid,  and  it  is  theorized  that  these
increased levels may constitute a compensatory mechanism and that, in early stages, uric
acid may have  antioxidant  properties,  that  paradoxically  become  pro-oxidant  in  later
stages of atherosclosis, when serum uric acid levels are increased, in a urate redox shuttle.
[91], [93]
Elevated levels of serum uric acid may also be related to impaired uric acid excretion due
to, for instance, low cardiac output and tissue hypoxia, with certain studies suggesting a
strong correlation between serum uric acid levels and Killip classification. [92]
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Procalcitonin
Procalcitonin (PCT) is a pro-hormone, involved in calcium metabolism, that is produced
mainly by the medullary C-cells of the thyroid gland and is know to be an inflammatory
biomarker,  that  is  found  in  increased  levels,  for  instance,  in  the  case  of  bacterial
infections, sepsis, major surgery, multiple trauma, cardiogenic shock and cardiac surgery.
[94]
PCT  is  thought  to  be  an  alternative  novel  marker  with  prognostic  value  in  ACS,  with
various  recent  studies  indicating  that higher  PCT  levels  are  associated  with  a  poorer
outcome and a higher risk of mortality in the following 6 months. [94]
Cystatin C
There seems to exist a close relationship between chronic kidney disease and subsequent
cardiovascular events in patients with ACS. Creatinine concentration and  estimation of
creatinine clearance are the most used means for estimation of renal function. However,
as creatinine concentration may be affected by various factors such as age and diet, it may
be unsensitive to small decreases in glomerular filtration rate (GFR). [95], [96]
Cystatin C is a cysteine protease inhibitor,  produced by all nucleated cells at a constant
rate  and  filtred  without  subsequent  reabsortion  to  the  blood  flow.  Cystatin  C
concentration is not altered by age, sex, muscle mass, exercise or diet and, therefore, it is
a good candidate for the estimation of GFR, with certain studies indicating that it may be a
better  endogenous  marker  of  GFR  than  serum creatinine.  Thus,  cystatin  C  may  be  a
promising  new  prognostic  biomaker  in  patients  with  ACS,  with  higher  concentrations
being associated with renal dysfunction and, therefore, with a poorer prognosis and more
subsequent cardiac events. [95], [96]
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1.3.6 –  Markers of necrosis
Troponins
Troponin,  located  on  the  thin  filament  of  the  myocardial  contractile  apparatus,  is  a
regulatory  complex  of  3  protein  subunits,  designated  troponin  C,  the  calcium-binding
component,  troponin  T,  the  tropomyosin-binding  component,  and  troponin  I,  the
inhibitory component. [97], [98]
Troponin T and troponin I constitute highly sensitive markers for myocardial injury. They
present  the  advantage  of  having  a  low  background concentration,  being  detected
immediately 4 to 9 hours after the onset of chest pain and remaining elevated up to 14
days after infarction, what gives them a wide diagnostic window. They present, however,
the inconvenient of not being specific for acute myocardial infarction being elevated also
in other conditions that lead to myocardial injury, such as  atrial fibrillation, congestive
heart failure, myocarditis, and myocardial contusions. [97], [98]
Cardiac  troponin  levels seem to have a linear correlation with  a worsening outcome,  as
levels greater than 0.4mg/mL are associated with a higher mortality rate within 42 days,
are inversely correlated with LVEF and are useful in the prediction of infarct size. [97], [98]
Myoglobin
Myoglobin is a heme muscle protein  abundant in the cytoplasm of cardiac and skeletal
muscle cells, constituting approximately 2% of muscle protein in both skeletal and cardiac
muscles.   Due  to its  low  molecular  weight,  myoglobin  is  rapidly  released  into  the
circulation after  acute myocardial infarction, reaching levels 5 to 10 times greater than
normal during the first 5 to 18 hours. [99]–[101]
Myoglobin  presents  the  inconvenient  of  having  poor  specificity for  acute  miocardial
infarction, due to its presence in skeletal muscle. [101], [102]
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Creatine  k  inase  
Creatine kinase (CK) is an enzyme present in many tissues, including myocardium and
skeletal muscle, in the form of 3 isoenzymes: MM, MB, and BB.  CK-MB is present in a
relatively high concentration in the myocardium and in patients with  acute miocardial
infarction a rise to twice the normal levels may be detected 4 to 9 hours after the onset of
chest pain, returning to baseline levels in 48 to 72 hours. CK-MB constitutes a marker of
cardiac tissue necrosis, as it is only released from myocardial cells upon death, not being
released with ischaemia. [98]–[100]
CK-MB should be determined as a percentage of total CK enzyme, in order to determine if
the source of the enzyme is cardiac  or skeletal  muscle, as a rise in CK-MB levels is not
specific to myocardial damage, occurring also in, for instance, skeletal muscle injury. A
relative index greater than 3.5%  is indicative of myocardial damage rather than skeletal
muscle injury. CK-MB levels are also useful in the determination of infarct size and risk of
re-infarction. [98], [100], [102]
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1.4 – Aims
Risk  stratification  in  patients  with  ACS is  very  important  in  the  determination  of  the
proper treatment strategy. Various clinical features are known to be associated with an
increased risk of a worse outcome in the event of an ACS and are taken into account in
various  risk  scores.  The main  aim  of  this  work  is  the  determination of  clinical
characteristics that are associated with a worse outcome in a group of patients with ACS
admitted  to  the  Cardiac  Intensive  Care  Unit  of  Hospital  Infante  D.  Pedro,  in  Centro
Hospitalar do Baixo Vouga (CHBV),  in order to identify potential  prognostic markers in
these patients, and the assessment of the association of these markers with other clinical
characteristics, in order to determine their influence in the physiology of patients with
ACS.
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2 – METHODOLOGY
2.1 – Data collection
A prospective observational study  was conducted in 980 patients  with ACS  admitted to
the Cardiac Intensive Care Unit of Hospital Infante D. Pedro, in Centro Hospitalar do Baixo
Vouga (CHBV), between January 2008 and June 2012. 
Data collected included general clinical information and information regarding cardiac risk
factors,  general  blood  test,  serum  cardiac  markers,  LVEF, provided  revascularization
therapy and previous and posterior cardiac events.
2.1.1 –  General clinical information
Data collected about the patient's general clinical information included date of admission,
date of discharge, duration of the hospitalization,  age,  gender,  race  and  reason of the
hospitalization. The reason of the hospitalization was separated in UA, STEMI and NSTEMI
2.1.2 –  Cardiac risk factors
The presence of cardiac risk factors was also determined. Risk factors evaluated included
the presence of a  familiar history of  CVD, personal history of  CVD, the presence of DM,
obesity,  hypertension or  dyslipidemia  and  whether  the  patients  were a  smokers,  ex-
smokers or alcoholics. 
Hypertension is defined as  a  persistent elevation  of blood  pressure to levels above 140
mm Hg in systolic blood pressure  and/or above 90 mm Hg in diastolic blood pressure.
[103]–[105]
Dyslipidemia  consists  in  alterations  in  lipoprotein  metabolism,  such  as  lipoprotein
overproduction  and  deficiency,  that  result  in  alterations  in  the  lipid  profile,  such  as
elevated levels of LDL  (> 110 mg/dL), elevated levels of triglyceride  (> 150 mg/dL) and
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decreased levels of HDL  (<  40 mg/dL  in men;  <  60 mg/dL  in women). Dyslipidemia is
characterized by the presence of at least one of these alterations.  [106]–[108]
DM  is  a  metabolic  disorder  in  which  a  defect  in  insulin  secretion  or  action  leads  to
hyperglycaemia and disturbances in carbohydrate, fat and protein metabolism. A patient
is diagnosed with DM when presenting a fasting plasma glucose ≥ 126 mg/dL,  a 2-hour
plasma  glucose  ≥200  mg/dL following  an  oral  glucose  tolerance  test,  a  glycated
hemoglobin  ≥  6,5%  or,  in  a  patient  with  classic  symptoms  of  hyperglycaemia  or
hyperglycaemic  crisis,  when presenting  a  random plasma glucose  ≥200 mg/dL.  In  the
absence of  unequivocal  hyperglycemia,  results  should be confirmed by repeat testing.
[109], [110] 
Obesity is defined as an excessive accumulation of body fat or adiposity. Although it does
not quantify total body adiposity, BMI, in kg/m2, is a weight-for-height index that presents
a  strong  correlation  with  adiposity  and  is  widely  used  in  the  assessment  of  obesity.
According to World Health Organization (WHO) and National Institute of Health, a patient
is  considered overweight  when presenting  a  BMI> 25,0  and obese with a  BMI> 30,0.
[106], [111]
2.1.3 –  General blood test
Data  related to general blood test was also assessed and included levels of hemoglobin
(g/dL), glucose (mg/dL) and lipid profile.
The evaluation of hemoglobin levels is important, as bleeding is a common complication
in patients with ACS. Anemia, defined by WHO as < 13  g/dL in men and < 12  g/dL in
women, is common in patients with ACS and is associated with an increased probability of
an adverse outcome. [112]–[114]
The assessment of glucose levels is important as elevated levels in patients without DM
are associated with short-term adverse outcomes.   Fasting plasma glucose levels should
ideally be less than126 mg/dL. [115]–[117]
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The  evaluation  of  the  patient's  lipid  profile  is  very  important  in  cardiovascular  risk
prediction and has now become a routine test. This evaluation included measurements of
the levels of total cholesterol (mg/dL) and LDL (mg/dL. [118]  Lipide profile was measured
in the first 24 hours after hospitalization, as studies indicate that measurements beyond
this period are not valid and do not reflect its habitual value, insofar as there seems to be
a reduction, that appears after 24 hours of onsent and remains for 2 to 3 months, in the
levels of total cholesterol, LDL and HDL. [119]–[122] 
2.1.4 –  Biomarkers
As previously discussed, biomarkers provide valuable information both in diagnosis, in the
determination  of  the  extent  of  myocardial  lesion  and  in  prognosis.  The  biomarkers
evaluated included troponin (ng/mL), CPR (mg/dL) and pro-brain natriuretic peptide (Pro-
BNP) (pg/mL).  In the case of troponin the level at time of admission and the maximum
value reached were both registered.
Troponins,  as  previously  mentioned,  are  cardiac  markers  of  necrosis,  important  for
diagnosis  and determination of  the extent of  myocardial  lesion.  They  seem to have a
linear  correlation  with  worsening  outcome,  with  levels  greater  than  0.4mg/mL being
associated with a higher mortality rate within 42 days. They are not normally detected in
the  serum  of  healthy  individuals  and,  therefore,  levels  greater  than  0,10  ng/ml  are
considered elevated. [123]
CRP  is  a  useful,  sensitive  biomarker  in  the  detection  of  ACS,  as  a  marker  of  a
proinflammatory state and plaque instability. In myocardial infarction there is normally an
accentuated rise  in  circulating  CRP  levels,  directly  correlated  with  the  extension  of
myocardial injury. CRP levels are considered elevated when they are greater than 6 mg/dL.
[67]–[70], [124], [125]  
Pro-BNP, levels constitute a simple and objective way of assessment of cardiac function
and  are  an indicator of  myocardial  injury. A  Pro-BNP of  less than 125 pg/ml excludes
cardiac  dysfunction  and  heart  failure  whereas  a  greater  value  is  indicative  of  cardiac
dysfunction and is associated with cardiac complications. [88], [126]
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2.1.5 –  Left ventricular ejection fraction
LVEF was also determined as it is an important measurement in the evaluation of global
contractile function.  It  was, therefore determined if  patients presented a normal LVEF
(>50%),  a  mildly  reduced  LVEF   (35-50%)  or  a  severely  reduced  LVEF  (<35%).  This
evaluation is important as a low LVEF is associated with higher risk of cardiac arrest and
arrhythmic death. [127], [128]
2.1.6 –  Provided revascularization therapy
Data concerning the provided revascularization therapy was also assessed, and included
the  number  of  vases  that  presented  and  obstruction  of  more  than  75%  in  the
catheterization,  if  the  patient  underwent  PTCA and  the  number  of  vases  that  were
revascularizated.
2.1.7 –   Events
The  presence  of  previous  and posterior  cardiac  events  was  also  assessed,  trough the
consultation of the patient’s medical records.
In  the  case  of  previous  cardiac  events  it  was  registered  if  the patient  had  previously
suffered from UA, NSTEMI, STEMI or stroke. 
In the case of posterior cardiac events  where characterized by date and type and were
divided in ACS,  stroke and others, such as  FA, CHF or cardiogenic shock.  In the case of
multiple events only the first event was considered. 
In the event of a death, date of death was registered, as well as whether death occurred
during the hospitalization or not.
Patients were followed until January 2014 and their individual follow-up period was also
registered.  The mean follow-up period was 33,25 ± 25,60 months.
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2.2 – Statistical analysis
Statistical analysis was performed using the version 19 of the software SPSS  (SPSS Inc.,
Chicago, Illinois, USA). 
Continue variable values were presented as mean ± standard deviation and categorical
variable values were presented as frequencies.
In continuous variables differences between groups were assessed using One-way Anova
or  Kruskal-Wallis test, followed  by  the  parametric  Student's  T-test.  Anova  analyzes
variances,  allowing  the  assessment  of  differences  between  several  different  groups
without multiple comparisons between group means.  Kruskal-Wallis is the advised non
parametric alternative when One-way Anova assumptions are not met. [129]–[131]  
Student's T-test is a parametric test presenting, thus, a stricter assumptions such as, in the
case of independent variables, normal distribution and homogeneity of variances.  [129],
[132], [133]
Proportion  differences  in  categorical  variables  were  assessed  using  the  asymptotic
Pearson’s X2 test and Fisher's Exact test, the advised alternative for smaller samples. [129],
[134], [135]
Hazard ratios, obtained through the  stepwise  Cox  Proportional  Hazards Model,  a useful
prognostic model in the prediction of clinical outcomes,  were used in the  evaluation  of
the prognostic impact of the predictors assessed. [136]
Survival curves, defined as the probability of surviving (absence of event) in a given length
of  time  (considering  time  in  small  intervals) were  obtained  using  the  Kaplan-Meyer
estimate. [137], [138]
Results were considered statistically significant when p <0,05.  
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3 – RESULTS
The  clinical  characteristics  of  study participants are summarized in table  8 and in  the
figures 1-15.
The analyzed sample included 980 caucasian individuals  that  were hospitalized  in CHBV
between 2008 and 2012,  688 (70,2%)  males and 292 (29,8%) females, from which  310
(31,6%)  were hospitalized due to STEMI,  579 (59,1%)  were hospitalized due to NSTEMI
and  91 (9,3%)  were hospitalized due to  UA.   These patients presented a mean age of
67,22 ± 12,99 years, with 798 (81,4%) of them being more than 55 years of age. The mean
follow-up period was 33,25 ± 25,60 months and during this period 172 patients (17,6%)
suffered  a  posterior  event  and  205 patients  (20,9%)  died,  with  64  (6,5%)  dying  from
cardiac causes. The 172 posterior events included 118 ACSs (12%), 19 strokes (1,9%) and
35 other events (3,6%).
In terms of risk factors, 41 (4,2%) patients had family history of ACS,  252 (25,7%) patients
had a previous case of ACS or  stroke,  681 (69,5%)  patients suffered from hypertension,
565 (57,7%)  patients suffered from dyslipidemia, 308 (31,4%)  patients suffered from DM,
173 (17,7%)  patients had  a  BMI greater than 30,  137 (14%)  patients were smokers,  93
(9,5%) patients were ex-smokers and 27 (2,8%) patients suffered from alcoholism.
The mean hemoglobin value was 13,67 ± 1,84 g/dL, with 30 patients (3,2%) presenting a
value of less than  10 g/dL,  138 patients  (14,9%)  presenting a value between 10  and 12
g/dL and 757 patients (81,8%) presenting a value greater than 12 g/dL, what translated in
222 anemic patients (24%). The mean glucose value was 151,61 ± 69,98 mg/dL, with 155
patients  (16,7%) presenting  a  value  of  less  than  100 mg/dL,  228  patients  (31,1%)
presenting a value between  100 and 126 mg/dL and 484 patients  (52,2%) presenting a
value greater than 126 mg/dL. The mean initial troponin value was 9,58 ± 23,61 ng/mL.
The mean maximum troponin value was 31,12 ± 44,71 ng/mL. The mean Pro-BNP value
was  3696,40  ± 9608,60 pg/mL.  The mean total  cholesterol  value was  183,55 ± 46,79
mg/dL.  The  mean  LDL  value  was  115,94 ± 39,02 mg/dL,  with  711  patients  (89,2%)
presenting avalue greater than 70 mg/dL. The mean CRP value was 2,02 ± 4,48 mg/dL. 
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PTCA was performed in  441  patients (59%),  with  356  patients  (57,4%) revascularizating
one blood vessel,  73  patients (12,1%) revascularizating 2 blood vessels and 10  patients
(1,7%) revascularizating 3 blood vessels
Table 8 – Clinical characteristics of study participants
Sample description
Age (years) 67,22 ±12,99
Age Class (n, %)
< 55 years 182 (18,6%)
> 55 years 798 (81,4%)
Gender (n, %)
Male 688 (70,2%)
Female 292 (29,8%)
Hospitalization Motive (n, %)
STEMI 310 (31,6%)
NSTEMI 579 (59,1%)
UA 91 (9,3%) 
Family History of ACS (n, %)
No 939 (95,8%)
Yes 41 (4,2%)
Previous event (n, %)
No 728 (74,3%)
Yes 252 (25,7%)
Type of Previous Event (n, %)
None 728 (74,3%)
ACS 202 (20,6%)
Stroke 41 (4,2%)
ACS+Stroke 9 (0,9%)
Hypertension (n, %)
No 299 (30,5%)
Yes 681 (69,5%)
Dyslipidemia (n, %)
No 415 (42,3%)
Yes 565 (57,7%)
BMI (n, %)
< 30 807 (82,3%)
> 30 173 (17,7%)
DM (n, %)
No 672 (68,6%)
Yes 308 (31,4%)
Note.  Values are presented as mean  ±  SD for continuous variables and as frequencies for categorical variables.  ACS: acute
coronary  syndrome;  BMI:  body  mass  index; DM:  diabetes  mellitus;  NSTEMI:  non–ST-segment  elevation  acute  myocardial
infarction; STEMI: ST-segment elevation myocardial infarction; UA: unstable angina
               (continued)
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Table 8 – Clinical characteristics of study participants (continued)
Sample description
Smoker (n, %)
No 843 (86%)
Yes 137 (14%)
Ex-smoker (n, %)
No 887 (90,5%)
Yes 93 (9,5%)
Alcoholic (n, %)
No 953 (97,2%)
Yes 27 (2,8%)
Hemoglobin (g/dL) 13,67 ±1,84
Hemoglobin Class (n, %)
< 10 g/dL 30 (3,2%)
10 -12 g/dL 138 (14,9%)
> 12 g/dL 757 (81,8%)
Anemia (n, %)
No 703 (76%)
Yes 222 (24%)
Glucose (mg/dL) 151,61 ± 69,98
Glucose Class (n, %)
< 100 mg/dL 155 (16,7%)
100 – 126 mg/dL 228 (31,1%)
> 126 mg/dL 484 (52,2%)
Inicial Troponin (ng/mL) 9,58 ± 23,61
Maximum Troponin (ng/mL) 31,12 ± 44,71
Pro-BNP (pg/mL) 3696,40 ± 9608,60
Total Cholesterol (mg/dL) 183,55 ± 46,80
LDL (mg/dL) 115,94 ± 39,02
LDL Class (n, %)
< 70 mg/dL 86 (10,8%)
> 70 mg/dL 711 (89,2%)
CRP (mg/dL) 2,02 ± 4,48
Obstructed Blood vessels (n, %)
0 139 (18,8%)
1 317 (42,8%)
2 175 (23,6%)
3 110 (14,8%)
PTCA (n, %)
No 306 (41%)
Yes  441 (59%)
Revascularizated blood vessels (n, %)
0 174 (28,9%)
1 356 (57,4%)
2 73 (12,1%)
3 10 (1,7%)
Note. Values are presented as mean ± SD for continuous variables and as frequencies for categorical variables. CRP: c reacive
protein; LDL: low density lipoprotein; PTCA: percutaneous transluminal coronary angioplasty;  Pro-BNP:  pro-brain natriuretic
peptide
                     (continued)
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Table 8 – Clinical characteristics of study participants (continued)
Sample description
LVEF Class (n, %)
> 50% 353 (67,5%)
35 – 50% 108 (20,7%)
 < 35% 62 (11,9%)
Posterior Event (n, %)
No 808 (82,4%)
Yes 172 (17,6%)
Type of Posterior Event (n, %)
No event 808 (82,4%)
ACS 118 (12%)
Stroke 19 (1,9%)
Other 35 (3,6%)
Death (n, %)
No 775 (79,1%)
Yes 205 (20,9%)
Cardiac Death(n, %)
No 916 (93,5%)
Yes 64 (6,5%)
Follow-up (Months) 33,25 ± 25,60
Note.  Values are presented as mean  ±  SD for  continuous variables and frequencies for  categorical  variables.   ACS:  acute
coronary syndrome; LVEF left ventricular ejection fraction
Figure 1 – Distribution (%) according to the hospitalization motive 
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Figure 2 – Distribution (%) according to the number of risk factors
Figure 3 – Distribution (%) according to the left ventricular ejection fraction
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Figure 4 – Distribution (%) according to the number of obstructed blood vessels
Figure 5 – Distribution (%) according to the number of revascularizated blood vessels
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Figure 6 – Distribution (%) according to the type of posterior event
Figure 7 – Histogram of age distribution (years)
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Figure 8 – Histogram of hemoglobin concentration distribution (g/dL)
Figure 9 – Histogram of glucose concentration distribution (mg/dL)
56                                                                              University of Aveiro – Masters in Molecular Biomedicine
Prognostic markers in 980 patients with ACS hospitalized in CHBV
Figure 10 – Histogram of initial troponin concentration distribution (ng/mL)
Figure 11 – Histogram of maximum troponin concentration distribution (ng/mL)
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Figure 12 – Histogram of Pro-BNP concentration distribution (pg/mL)
Figure 13 – Histogram of total cholesterol concentration distribution (mg/dL)
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 Figure 14 – Histogram of LDL concentration distribution (mg/dL)
Figure 15 – Histogram of CRP concentration distribution (mg/dL)
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The assessment of significant differences in the mean values of age, hemoglobin, glucose,
initial troponin,  maximum troponin,  Pro-BNP,  total  cholesterol, LDL  and CRP in different
groups of patients, using Student's T-Test presented various statistically significant results,
that are summarized in table 9.
Patients  that  had  a  posterior event  were  older  and  presented  significantly lower
hemoglobin concentrations than patients that did not suffer a posterior event. 
Patients  that  had  a  posterior  stroke  were  older  and presented  significantly lower
hemoglobin concentrations than patients that did not suffer a posterior stroke. 
Patients that suffered another other type of posterior event were significantly older than
patients that did not suffer any other type of posterior events
Male patients were  younger  and  presented  significantly higher hemoglobin
concentrations and lower Pro-BNP concentrations than female patients.
Patients  younger than 55 years of age presented  significantly higher hemoglobin,  total
cholesterol and LDL concentrations and lower initial troponin and Pro-BNP concentrations
than patients older than 55 years of age.
Anemic patients  were older and presented  significantly higher initial troponin, Pro-BNP
and CRP  concentrations  and lower total  cholesterol  and LDL concentrations than  non
anemic patients.
Patients  that  did  underwent  PTCA  were  younger  and presented  significantly higher
hemoglobin and  maximum troponin concentrations than  the  patients  that  did  not
underwent PTCA.
Patients  that died  were  older  and presented  significantly lower hemoglobin,  total
cholesterol and LDL concentrations and higher glucose, initial troponin, Pro-BNP and CRP
concentrations than the patients that did not died. 
Patients  that died  due to cardiac reasons  were older and presented  significantly lower
hemoglobin concentrations and higher initial troponin, maximum troponin, Pro-BNP and
CRP concentrations than the patients that did not die due to cardiac reasons.
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Table 9 – Comparison of the mean values of  age, hemoglobin, glucose,  initial troponin,
maximum troponin, Pro-BNP, total cholesterol, LDL and CRP in different groups of patients
Mean ± SD T p Value
No Posterior Event Posterior Event
Age 67,18 ± 13,05 71,18 ± 11,87 -4,137 0,000
Hemoglobin 13,76 ± 1,79 13,20 ± 1,995 3,408 0,001
No Posterior Stroke Posterior Stroke
Age 67,71 ± 12,93 78.3 ± 8,32 -5,594 0,000
Hemoglobin 13,70 ± 1,83 12,13 ± 1,68 3,586 0,003
No Other Posterior Events Other Posterior Events 
Age 67,67 ± 13,02 74,83 ± 8,02 -5,045 0,000
Male Female
Age 65,52 ± 12,85 73,57 ± 11,31 -9,776 0,000
Hemoglobin 14,12 ± 1,72 12,59 ± 1,65 12,473 0,000
Pro-BNP 2952,60 ± 8144,44 5402,46 ± 12191,14 -2,119 0,029
< 55 Years of Age  > 55 Years of Age
Hemoglobin 14,75 ± 1,36 13,42 ± 1,85 10,833 0,000
Initial Troponin 5,13 ± 14,40 10,63 ± 25,19 -3,869 0,000
Pro-BNP 710,84 ± 1211,38 4353,84 ±10487,48 -6,627 0,000
Total Cholesterol 201,14 ± 48,85 178,96 ± 45,16 5,523 0,000
LDL 130,39 ± 40,12 112,17 ± 37,86 5,437 0,000
                                   No anemia  Anemia
Age 65,31 ± 12,92 75,42 ± 10,188 -12,041 0,000
Initial Troponin 7,48 ± 18,28 16,22 ± 34,87 -3,576 0,000
Pro-BNP 2369,89 ± 5812,83 7850,49 ± 15955,83 -3,592 0,000
Total Cholesterol 189,05 ± 45,68 164,20 ± 45,40 6,310 0,000
LDL 120,33 ± 38,34 100,44 ± 37,496 6,039 0,000
CRP 1,65 ± 4,195 3,28 ± 5,17 -4,074 0,000
Note.  Student's T-test  results are presented as  Mean  ±  SD,  and statistics T and p Value. Results were considered statically
significant when p < 0,005. CRP: C reactive protein; LDL: low density lipoprotein; Pro-BNP: pro-brain natriuretic  peptide
          (continued)
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Table 9 – Comparison of the mean values of  age, hemoglobin, glucose,  initial troponin,
maximum troponin, Pro-BNP, total cholesterol, LDL and CRP in different groups of patients
(continued)
Mean ± SD t p Value
Did not underwent PTCA Underwent PTCA
Age 68,04 ± 11,77 64,00 ± 12,26 4,501 0,000
Hemoglobin 13,69 ± 1,81 14,08 ± 1,72 -2,907 0,000
Maximum Troponin 21,28 ± 28,22 40,84 ± 56,30 -6,099 0,000
Did not Die Died
Age 65,39 ± 12,66 77,49 ± 8,91 -15,700 0,000
Hemoglobin 13,98 ± 1,68 12,41 ± 1,92 10,070 0,000
Glucose 148,65 ± 68,11 163,87 ±76,05 -2,457 0,015
Initial Troponin 7,22 ±17,86 19,31 ± 37,78 -4,193 0,000
Pro-BNP 2338,17 ± 7029,42 11101,56 ± 16261,19 -4,528 0,000
Total Cholesterol 186,92 ± 45,46 165,03 ± 49,74 4,838 0,000
LDL 118,36 ± 37,88 102,53 ± 42,53 4,168 0,000
CRP 1,63 ± 4.13 3,70 ± 5,41 -4,650 0,000
Without Cardiac Death With Cardiac Death
Age 67,25 ± 12,96 77,53 ± 7.90 -6,264 0,000
Hemoglobin 13,76 ± 1,80 12,41 ± 1,97 5.164 0,000
Initial Troponin 8,45 ±21.78 26,28 ± 38,71 -5,711 0,000
Maximum Troponin 7,22 ±17,86 19,31 ± 37,78 -2,017 0,048
Pro-BNP 3085,70 ± 8329,34 15070,79 ± 19976,59 -4,528 0,000
CRP 1,84 ± 4.29 4,65 ± 6,11 -4,600 0,000
Note.  Student's T-test  results are presented as  Mean  ±  SD,  and statistics T and p Value. Results were considered statically
significant when p < 0,005.  CRP: C reactive protein; LDL: low density lipoprotein;  PTCA: percutaneous transluminal coronary
angioplasty; Pro-BNP: pro-brain natriuretic peptide
The assessment of significant differences in the values of age hemoglobin, glucose, initial
troponin,  maximum  troponin,  Pro-BNP,  total  cholesterol, LDL  and CRP  according to the
patient´s hospitalization motive,  LVEF and  type of posterior event  was done using  One-
way Anova in the cases where Levine's test confirmed the homogeneity of variances and
the Kruskal-Wallis test in the cases where Levine's test did not confirm the homogeneity
of variances. The significant results of these tests are summarized in table 10.
In the case of  the hospitalization motive,  there was a statistically significant difference
between  groups  in  age and  in  the  levels  of  hemoglobin,  initial  troponin,  maximum
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troponin, Pro-BNP and CRP.
In the case of  the LVEF,  there was a significant difference between groups in age and in
the levels of hemoglobin, initial troponin, maximum troponin, Pro-BNP and CRP.
In the case of  the type of posterior event, there was a statistically significant difference
between groups in age and in the levels of hemoglobin and Pro-BNP. 
Table 10 – Assessment of differences in the values of age hemoglobin,  glucose,  initial
troponin,  maximum troponin,  Pro-BNP, total  cholesterol, LDL and CRP between different
groups of patients
Groups Kruskal-Wallis One-way Anova
H p Value F p Value
Hospitalization Motive
Age 11,212 0,004
Hemoglobin 3,582 0,028
Initial Troponin 81,193 0,000
Maximum Troponin 229,589 0,000
Pro-BNP 22,143 0.000
CRP 11,650 0,003
LVEF
Age 24,002 0,000
Hemoglobin 17,143 0,000
Initial Troponin 14,077 0,001
Maximum Troponin 13,164 0,001
Pro-BNP 52,894 0,000
CRP 16,670 0,000
Posterior Event
Age 28,190 0,000
Hemoglobin 5,924 0,001
Pro-BNP 16,494 0,001
Note.  One-way Anova was used  in the cases where Levine's test confirmed the homogeneity of variances  and in the cases
where Levine's test did not confirm the homogeneity of variances the Kruskal-Wallis test was used. Results were considered
statically  significant  when p  <  0,005.  CRP:  C  reactive  protein;  LVEF:  left  ventricular  ejection  fraction;  Pro-BNP:  pro-brain
natriuretic peptide
Pearson's X2 test was used in the assessment of  associations between the presence of a
posterior event, gender, age, anemia, PTCA death and other clinical variables.  When, in
Pearson's X2 test, there were more than 20% of cells with an expected count of less than
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5,  Fisher's  exact  test was  used  instead.  The significant  results  of  these  tests  are
summarized in table 11.
There was a statistically significant association between posterior event and age, gender,
presence  of  a  previous  event,  hypertension,  dyslipidemia,  BMI,  being  an  ex-smoker,
hemoglobin class, anemia, LVEF  class and  with death.  Patients that suffered a posterior
event were older and more prone to be female; had a higher prevalence of hypertension,
dyslipidemia and anemia; had a higher BMI, a lower hemoglobin class and a lower LVEF
class; were more prone to have had a previous event, less prone to being ex-smokers and
more prone to death.
Posterior  ACS presented  a  statistically  significant  association  with  previous  event,
dyslipidemia,  BMI,  anemia,  glucose class and with LVEF  class.  Patients that  suffered a
posterior ACS were more prone to have had a previous event; had a higher prevalence of
dyslipidemia and anemia; had a higher BMI, a lower glucose class and a lower LVEF class.
Posterior stroke presented a statistically significant association with age, gender, previous
event, hypertension,  hemoglobin  class,  anemia and  death.  Patients  that  suffered  a
posterior stroke were older, more prone to be female, more prone to have had a previous
event  and more prone to death; had a higher prevalence of hypertension  and  a higher
hemoglobin class.
Patient  gender presented a statistically  significant  association with,  age,  hypertension,
being a  smoker,   being an ex-smoker,  alcoholism, hemoglobin class, anemia,  number of
obstructed blood vessels and death.  Male patients were younger and more prone to be
smokers  and ex-smokers;  had  a  lower  prevalence  of hypertension  and anemia  and  a
higher prevalence of alcoholism; had a higher hemoglobin class and a higher number of
obstructed vases and were less prone to death.
There was a statistically significant association  between age and family history of ACS,
previous  event,  hypertension,  DM,  being  a  smoker, being  an  ex-smoker,  alcoholism,
hemoglobin class, anemia, LDL class, number of obstructed blood vessels, PTCA, number
of revascularizated blood vessels, LVEF and death. Older patients were less prone to have
family history of ACS, less prone to be smokers and ex-smokers and more prone to have
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had a previous event;  had a higher prevalence of hypertension, DM  and anemia and a
lower prevalence of alcoholism; had a lower hemoglobin class, a lower LDL class, a lower
LVEF  class  and a  higher number of obstructed blood vessels  and revascularizated blood
vessels; were less prone to have had a PTCA and more prone to death.
There  was  a  statistically  significant  association  between  anemia and hospitalization
motive family history of ACS, previous event, hypertension, DM, being a smoker, LDL class,
number  of  obstructed  blood vessels,  PTCA, number  of  revascularizated blood vessels,
LVEF class and death. Anemic patients were more prone to have been hospitalized due to
STEMI,  more prone to have had a previous event,  less prone to have a family history of
ACS and less prone to be smokers; had a higher prevalence of hypertension and DM;  had
a  lower LDL  a lower LVEF class  and a  higher number of  obstructed blood vessels  and
revascularizated blood vessels;  were  less prone to have had a PTCA and more prone to
death.
There was a statistically significant association between PTCA and hospitalization motive,
previous event,  hypertension,  being a smoker and number of obstructed blood vessels.
Patients that underwent PTCA were more prone to have been hospitalized due to STEMI,
more prone  to be smokers and  less prone to have had a previous event;  had a lower
prevalence of HTA and a higher number of obstructed blood vessels.
There was a statistically significant association between death and hospitalization motive,
family history of ACS, previous event, dyslipidemia, BMI, DM, being a smoker, being an ex-
smoker,  hemoglobin  class,  LDL  class,  number  of  obstructed  blood vessels, number  of
revascularizated blood vessels and LVEF class. Patients that died were less prone to have
been hospitalized due to UA, less prone to have a family history of ACS and less prone to
be smokers or ex-smokers and were  more prone to have had a previous event;  had a
lower prevalence of  dyslipidemia  and a higher prevalence of DM;  had a lower BMI,  a
lower hemoglobin  class, a lower  LDL class,  a lower LVEF class  and a  higher number of
obstructed blood vessels and revascularizated blood vessels.  Patients  that died  due to
cardiac reasons were older, more prone to be female and less prone to be smokers; had a
lower prevalence of dyslipidemia and DM and a higher prevalence of anemia; had a lower
hemoglobin class, a lower LDL class and a lower LVEF class.
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There was a statistically significant association  between LVEF and hospitalization motive
and previous event.  Patients with a lower LVEF class were more prone ho have been
hospitalized due to STEMI and more prone to have had a previous event. 
Table 11 – Assessment of the association between various clinical characteristics
                                            N(%)
Pearson's X2 test Fisher's
exact
test X
2 P value
No Posterior Event Posterior Event
>55 years of age 647 (80,1%) 151 (87,8%) 5,584 0,018
Female gender 226 (28,0%) 66 (38,8%) 7,335 0,007
Previous Event 175 (21,7%) 77(48,8%) 39,646 0,000
Hypertension 544 (67,7%) 137 (79,5%) 10,160 0,001
Dyslipidemia 448 (55,4%) 117 (68,0%) 9,189 0.002
BMI > 30 129 (16,0%) 44 (25,6%) 9,021 0,003
Ex-Smoker 85(10,5%) 8 (4,7%) 5,686 0,017
Hemoglobin < 10g/L 22 (2,8%) 8 (5,3%) 12,581 0,002
Anemia 169 (21,9%) 53 (34,9%) 11,779 0,001
LVEF <35% 43 (9,6%) 19 (24,7%) 26,747 0,000
Death 149 (18,4%) 56 (32,6%) 17,086 0,000
 No Posterior ACS Posterior ACS
Previous event 200 (23,2%) 52 (44,1%) 23,657 0,000
Dyslipidemia 481 (55,8%) 84 (71,2%) 10,064 0,002
BMI > 30 140 (16,2%) 33 (28.0%) 9,815 0,002
Anemia 185 (22,6%) 37 (34,9%) 7,806 0,005
Glucose < 100 mg/dL 135 (15,2%) 30 (28,0%) 11,154 0,004
LVEF <35% 55 (11,5%) 7 (15,2%) 15,211 0,000
No Posterior Stroke Posterior Stroke 
>55 years of age 779 (81,1) 19 (100%) 0,034
Female gender 282 (29,3%) 10 (52,6%) 4,830 0,028
Previous event 242 (25,2%) 10 (52,6%) 0,014
Hypertension 663 (69,0%) 18 (94,7%) 5,825 0,016
Hemoglobin  > 12 g/L 750 (82,4%) 7 (46,7%) 0,003
Death 195 (20,3%) 10 (52,6%) 0,002
Note: Pearson's X2 test was used in the assessment of associations between various variables. When, in Pearson's X2 test, there
were more than 20% of cells with an expected count of less than 5,  Fisher's exact test was used.  Results were considered
statically significant when p < 0,005.  ACS: acute coronary syndrome; BMI: body mass index; LVEF: left ventricular ejection
fraction; 
         (continued)
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Table 11 – Assessment of association between various clinical characteristics (continued)
                                               N (%)
Pearson's X2 test Fisher's
exact
testX
2 P value
Male Female
< 55 years of age 158 (23,0%) 24 (8,2%) 29,476 0,000
Hypertension 462 (67,2%) 219 (75%) 5,956 0,015
Smoker 121 (17,6%) 16 (5,5%) 24,991 0,000
Ex-smoker 90 (13,1%) 3 (1,0%) 34,678 0,000
Alcoholism 24 (3,5%) 3 (1,0%) 4,634 0,031
Hemoglobin > 12 g/dL 574 (87,8%) 183 (67,5%) 52,824 0,000
Anemia 140 (21,4%) 82 (30,3%) 8,230 0,004
3 obstructed blood Vessels 88 (15,9%) 22 (11,8%) 7,913 0,048
Death 131 (19,0%) 74 (25,3%) 4,921 0,027
< 55 years of age > 55 years of age
Family history of ACS 17 (9,3%) 24 (3,0%) 14,828 0,000
Previous event 30 (17,6%) 220 (27,6%) 7,737 0,005
Hypertension 100 (54,9%) 581 (72,8%) 22,302 0,000
DM 45 (24,7%) 263 (33,0%) 4,660 0,031
Smoker 82 (45,1%) 55 (6,9%) 179,486 0,000
Ex-smoker 27 (14,8%) 66 (8,3%) 7,435 0,006
Alcoholism 12 (6,6%) 15 (1,9%) 12,290 0,000
Hemoglobin < 10 g/dL 1 (0,6%) 29 (3,9%) 37,261 0,000
Anemia 12 (6,8%) 210 (2,8,1%) 35,585 0,000
LDL > 70 mg/dL 155 (93,9%) 556 (88,0%) 4,836 0,028
3 obstructed blood vessels 15 (9,3%) 95 (16,4%) 18,275 0,000
PTCA 106 (66,3%) 335 (57,1%) 4,381 0,036
3 revascularizated blood vessels 1 (0,8%) 9 (1,9%) 8,397 0,038
LVEF < 35% 5 (4,8%) 57 (13,6%) 6,277 0,043
Death 4 (2,2%) 201 (25,2%) 47,351 0,000
Note. Pearson's X2 test was used in the assessment of associations between various variables. When, in Pearson's  X2 test, there
were more than 20% of cells with an expected count of less than 5,  Fisher's exact test was used.  Results were considered
statically significant when p < 0,005. ACS: acute coronary syndrome; DM: diabetes mellitus; LDL: low density lipoprotein;  LVEF:
left ventricular ejection fraction; PTCA: percutaneous transluminal coronary angioplasty
                                                                                                                                            (continued)
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Table 11 – Assessment of association between various clinical characteristics (continued)
                                                    N (%)
Pearson's X2 test Fisher's
exact
test
X2 P value
 No Anemia Anemia
Family history of ACS 37 (5,7%) 4 (1,8%) 4,772 0,029
Previous event 151 (21,5%) 79 (35,6%) 17,970 0,000
Hypertension 462 (65,7%) 175 (78,8%) 13,526 0,000
Hospitalization due to NSTEMI 397 (56,7%) 149 (67,1%) 7,959 0,019
DM 190 (27,0%) 94 (42,3%) 18,601 0,000
Smoker 124 (17,2%) 14 (6,3%) 16,099 0,000
 LDL > 70 mg/dL 576 (92,3%) 134 (78,4%) 27,335 0,000
3 obstructed blood vessels 80 (14,1%) 25 (18,1%) 11,681 0,009
PTCA 356 (62,2%) 71 (50,7%) 6,222 0,013
3 revascularizated blood vessels 2 (0,4%) 8 (7,7%) 36,965 0,000
LVEF < 35% 35 (8,7%) 25 (22,7%) 17,060 0,000
Death 86 (12,2%) 94 (42,3%) 97,592 0,000
No PTCA PTCA
Hospitalization due to STEMI 63 (20,6%) 197 (44,7%) 47,213 0,000
Previous event 90 (29,4%) 94 (21,3%) 6,379 0,012
Hypertension 236 (77,1%) 290 (65,8%) 11,200 0,001
Smoker 33 (10,8%) 87 (19,7%) 10,717 0,001
2 obstructed blood vessels 54 (18,5%) 119 (27,0%) 256,982 0,000
 Did not die Died
Hospitalization due to NSTEMI 446 (57,5%) 133 (64,9%) 9,578 0,008
Family history of ACS 40 (5,2%) 1 (0,5%) 8,833 0,003
Previous event 180 (23,2%) 72 (35,1%) 12,011 0,001
Dyslipidemia 466 (60,1%) 99 (48,3%) 9,303 0,002
BMI < 30 148 (19,1%) 25 (12,2%) 5,312 0,021
DM 226 (29,2%) 82 (40,0%) 8,837 0,003
Smoker 127 (16,4%) 10 (4,9%) 17,857 0,000
Ex-smoker 83 (10,7%) 10 (4,9%) 6,419 0,011
Hemoglobin < 10 g/dL 14 (1,9%) 16 (8,9%) 100,447 0,000
LDL > 70 618 (91,6%) 93 (76,2%) 25,212 0,000
3 obstructed blood vessels 93 (14,4%) 17 (17,5%) 14,763 0,002
3 revascularizated blood vessels 8 (1,5%) 2 (2,4%) 13,740 0,003
LVEF < 35% 32 (7,1%) 30  (40,5%) 72,337 0,000
Note. Pearson's X2 test was used in the assessment of associations between various variables. When, in Pearson's X2 test, there were
more than 20% of cells with an expected count of less than 5, Fisher's exact test was used. Results were considered statically significant
when p < 0,005. BMI: body mass index; DM: diabetes mellitus; LDL: low density lipoprotein;   LVEF: left ventricular ejection fraction;
NSTEMI:  non–ST-segment elevation acute myocardial infarction; PTCA: percutaneous transluminal coronary angioplasty;  STEMI:  ST
segment elevation myocardial infarction; UA: unstable angin      
          (continued)
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Table 11 – Assessment of association between various clinical characteristics (continued)
                                                    N (%)
Pearson's X2 test Fisher's
exact
test 
X2 P value
Without cardiac death     Cardiac Death
>55 years of age 735 (80,2%) 64 (98,4%) 13,99 0,000
Female Gender 265 (27,8%) 137 (42,2%) 5,026 0,025
Hypertension 645 (70,4%) 36 (56,3%) 5,661 0,017
Dyslipidemia 538 (58,7%) 27 (42,2%) 6,708 0,012
Smoker 134 (14,6%) 3 (4,7%) 4,916 0,027
Hemoglobin < 10 g/dL 24 (2,8%) 16 (10%) 28,582 0,000
Anemia 446 (57,5%) 137 (64,9%) 23,779 0,000
LVEF < 35% 52 (10,3%) 10  (52,8%) 37,254 0,000
 LVEF < 35% LVEF > 50%
Hospitalization due to STEMI 40 (64,5%) 196  (55,5%) 20,240 0,000
Previous event 21 (33,9%) 10  (%) 6,484 0,039
Note. Pearson's X2 test was used in the assessment of associations between various variables. When, in Pearson's X2 test, there
were more than 20% of cells with an expected count of less than 5,  Fisher's exact test was used.  Results were considered
statically significant when p < 0,005. LVEF: left ventricular ejection fraction; STEMI:  ST-segment elevation myocardial infarction
The  Kaplan-Meier estimate allowed the  assessment of significant  differences in survival
distribution in function of gender, age, hemoglobin class, presence of anemia, LVEF class,
motive of  hospitalization,  presence of  a  family history of  ACS,  presence of  a previous
event,  type  of  previous  event,  presence  of  hypertension, presence  of  dyslipidemia,
presence of DM,  BMI, being a smoker,  being an ex-smoker, presence of alcoholism, LDL
class, glucose class and PTCA, as reported in the survival-curves in the figures 16-26.
There was a statistically  significant  difference in survival distribution in  function of age,
gender, presence or absence of a previous event,  type of previous event,  presence or
absence of hypertension, presence or absence of dyslipidemia, BMI, being an ex-smoker,
hemoglobin class, presence of anemia and LVEF class.
Younger age, male gender, absence of a previous event, absence of hypertension, absence
of dyslipidemia, lower BMI class, being an ex-smoker, higher hemoglobin class, absence of
anemia and a  lower LVEF class are  statistically associated with a  higher probability  of
absence of a posterior event.
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Figure 16 -   Curves of the probability of absence of a posterior event in male and female
patients
Figure 17 – Curves of the probability of absence of a posterior event in patients younger
than 55 years of age and in patients older than 55 years of age
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Figure 18 – Curves of the probability of absence of a posterior event  according to the
patient's hemoglobin class
Figure 19 – Curves of the probability of absence of a posterior event in patients with and
without anemia
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Figure 20 – Curves of the probability of absence of a posterior according to the patient's
LVEF class
Figure 21 – Curves of the probability of absence of a posterior  event in patients that
suffered and did not suffer a previous event
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Figure 22 – Curves of the probability of absence of a posterior event according to the type
of previous event
Figure 23 – Curves of the probability of absence of a posterior event in patients with and
without hypertension
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Figure 24 – Curves of the probability of absence of a posterior event in patients with and
without dyslipidemia
Figure 25 –  Curves of the probability of absence of a posterior event in patients with and
without a BMI greater than 30
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Figure 26 –  Curves of the probability of absence of a posterior event in patients that are
and aren't ex-smokers
The  Cox  proportional  hazards model  was  used  in  the  evaluation  of  the  relative  risk
associated with  age, hemoglobin, glucose,  initial troponin,  maximum troponin,  Pro-BNP,
total cholesterol, LDL and CRP. 
Without adjustment for other variables,  older age, lower hemoglobin levels and higher
Pro-BNP levels are associated with an increased risk of occurrence a posterior event.
With the adjustment for gender, previous event, DM, BMI and number of risk factors,
older age was associated with an increased risk of occurrence of a posterior event. With
the adjustment for  age,  gender,  previous  event,  DM, BMI and number of  risk  factors,
higher  Pro-BNP levels  are  associated with an increased risk  of  occurrence a posterior
event. These results are summarized in table 12.
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TABLE 12 – Adjusted and unadjusted relative hazard ratios (95% CI) for the occurrence of a
posterior event according to age, hemoglobin and pro-BNP concentrations
Variable Hazard Ratio p Value
Model 1
Age 1,023 (1,010 – 1,036) 0,000
Hemoglobin 0,876 (0,807 – 0,949) 0,001
Pro-BNP 1,000 (1,000 – 1,000) 0,038
Model 2 Age 1,026 (1,012 – 1,041) 0,000
Model 3 Pro-BNP 1,000 (1,000 – 1,000) 0,019
Note: Model 1: Without adjustment; Model 2: After adjustment for gender, presence of previous event, DM,BMI and number
of risk factors; Model 3: After adjustment for age, gender, presence of previous event, DM,BMI and number of risk factors. Pro-
BNP: pro-brain natriuretic peptide
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4 – DISCUSSION
4.1 – Gender
The risk of CVD in women is often underestimated due to the perception that females are
protected against  ACS.  However,  CVD is  the leading  cause of  death  in  both man and
women, with data from WHO indicating  that,  in Europe, it is responsible for 43% of  all
deaths in men and 55% of all deaths in women. Various studies also indicate that female
gender in associated with a worse outcome in the event of an ACS, despite the fact that
females are less likely to have significant coronary narrowing and relatively more often
have preserved left ventricular function, what constitutes a “gender-paradox”. [139], [140]
Our results indicate that men with ACS are significantly younger than women and that the
proportion of  female patients with ACS seems to rise with age.  This  corroborates the
notion that women in fertile age have a lower risk of cardiac events that increases with
menopause.  The  repercussion of  coronary  risk  factors  in  women,  especially  during
menopause, is different than in male, due to specific hormonal effects during menopausal
period. Menopause is associated with a decline in the levels of estrogen, that result in a
decrease  in  the  activity  of  LDL  receptors  and,  therefore,  in  an  increase  in  LDL
concentration that, associated with a decrease in HDL levels, may explain the increase in
coronary  risk  in  postmenopausal  women.  This  is  corroborated  by  the  fact  that  total
cholesterol levels in women normally reach a peak between 55 and 65 years of age, about
a decade later than in men. [49], [140]
In our study, men presented significantly higher hemoglobin concentrations, while women
presented a higher prevalence of anemia, which may play a role in the worse prognosis
verified in women, as anemia is a known indicator of an adverse outcome in ACS, leading
to to a greater reduction in oxygen flow to the miocardium. 
It  is  also  important  to  notice  that  women  presented  statistically  significant  higher
concentrations of Pro-BNP, what may be an indicator of a greater infarct size and cardiac
dysfunction in women, although various studies have showed that the levels of Pro-BNP
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are gender dependent, with higher levels in women being independent of other baseline
variables such as blood pressure or renal function. [141]
In women there is normally a higher prevalence of risk factors and co-morbidities,  what
may also  contribute  to  a  worse  outcome.  That  was  also  verified with  our  results,  as
women  presented  a  higher  prevalence  of  hypertension  and  anemia.  It  is,  however,
interesting to notice that our study found no significant differences  between men and
women in  the  prevalence  of  obesity,   dyslipidemia  and  DM,  in  spite  of  the  higher
prevalence in women reported by various studies. Men presented a greater prevalence of
smoking and alcoholism, possibly due to socio-cultural factors.
There was also higher incidence of death and posterior events in women  and survival
curves revealed a significantly higher probability of the occurrence of a posterior event in
the case of women, what indicates that women have a worse prognosis after ACS.  This
may be explained by a worse clinical profile as, at presentation, women are older and
have more co-morbidities such as hypertension, DM, dyslipidemia and anemia. Also, there
is a higher incidence of silent ischaemia or atypical symptoms in women, possibly due to
older age and more co-morbidities,  what  may cause an increase in treatment-seeking
delay and result in a greater infarct size in the case of an acute myocardial infarction and
more serious consequences, what could explain the greater Pro-BNP concentrations found
in  women. Finally,  studies  indicate  that  in  women  there  is  normally  a  less  invasive
diagnostic approach and that women with ACS generally receive less aggressive treatment
and are less likely to undergo coronary angiography or have revascularization what  may
also  explain  contribute  to  their worse  prognosis.    [139],  [141],  [142] It  is,  however,
interesting  to  notice  that  our  study  found  no  significant gender  bias  in  utilization  of
invasive revascularization procedures or in the number of revascularizated blood vessels.
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4.2 – Age
Age is a very important determinant in the outcome of ACS, taken into account in various
risk assessment scores. Older age is not only an important risk factor for ACS but has also
a very important association with a poorer prognosis, what was also verified in our study,
where  older  age  was  significantly  associated  with  a higher  incidence  of  death  and
posterior events and where survival curves also revealed a significantly higher probability
of the occurrence of a posterior event in the case of  older patients. Various factors are
associated with this worse outcome in older patients.
An accurate recognition of ACS on initial  presentation is a key for the minimization of
morbidity  and  mortality.  Older  patients  frequently have  a  more  atypical  clinical
presentation,  a higher incidence of silent ischaemia  and their initial ECGs are less likely
diagnostic  of  ACS  what  may  result  in  an  increase  in  treatment-seeking  delay in  an
uncertainty about the initial diagnosis, potentially hindering timely ACS therapies,  what
may lead to a greater infarct size in the case of an acute myocardial infarction.[143] This
could explain the higher concentrations of initial troponin and Pro-BNP that we found in
older patients. This is corroborated by the findings of Boersma et al. [144], as they found a
more pronounced association between older age and mortality  in patients with  acute
myocardial  infarction rather  than  in  those  with  UA,  what  suggests  that  the  relation
between age  and  outcome  is  associated  with  the presence  and  extent  of  myocardial
necrosis at admission. 
Older patients also presented a higher prevalence of cor-morbilities and risk factors, such
as  hypertension,  DM  and  anemia,  and  had  higher  concentrations  of  LDL  and  total
cholesterol what may also contribute to a worse outcome. The exceptions were the lower
prevalence in older patients of smoking and alcoholism.
Furthermore, older patients presented a lower LVEF, what indicates that they have a less
preserved left ventricular systolic function, possibly due to greater infarction sizes and due
to the greater prevalence of previous events that may have result in an already impaired
LVEF, what further contributes to a poor prognosis. 
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It is also important to notice that older patients normally have a greater frequency of
physiological and cognitive impairment or disability and, as previously mentioned, present
a greater number of co-morbidities which enhance their age-related risk. Elderly patients
may also present varied  drug metabolism and a greater prevalence of renal impairment
and decreasing lean body weight what may difficult the correct dosing of medication. All
these factors may increase the tendency to a more conservative option of treatment, in
spite  of  these  being  higher  risk  ACS  patients,  what  may  also  contribute  to  a  worse
outcome. [143] Elderly patients have been shown to receive less aggressive anti-ischaemic
therapy  and  to  be  less  likely  to  undergo  coronary  angiography  and  revascularization
procedures. This was also verified in our study where, in spite of having a greater number
of obstructed blood vessels, older patients were significantly less likely to undergo PTCA.
The  elderly  patients  that  did  undergo  PTCA  presented  a  greater  number  of
revascularizated blood vessels than younger patients.
Finally,  it is very interesting to notice there was a higher prevalence of family history of
ACS in younger patients, what seems to indicate that, in fact, genetic factors may have an
important role in the pathogenesis of ACS and, therefore, certain genetic characteristics
may make individuals more prone to ACS, leading to an earlier onset of the disease. The
determination of these genetic factors is, therefore, very important, in order to allow an
earlier determination of families at a higher risk and an earlier clinical  intervention in
order to modify risk factors and prevent the development of the disease.
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4.3 – Anemia
Anemia is known to be a strong indicator of a higher probability of an adverse outcome in
patients  with  ACS  what  is  corroborated  by  our  findings  as  there  was  a significant
association between anemia and death or occurrence of a posterior event. We also found
significant  lower concentrations of hemoglobin in patients that died or had any kind of
posterior event when compared to those who didn't. Also the survival curves and hazard
ratios obtained  confirmed  that  lower  hemoglobin  concentrations  and  anemia  are
associated with a higher probability of occurrence of a posterior event. 
Anemia  causes a decrease blood oxygen levels,  what may be arrhythmogenic,  directly
exacerbate myocardial ischaemia or activate the sympathetic nervous system and result in
hypoperfusion. On one side, a reduction in hemoglobin levels means that blood will have
a lower capacity of oxygen delivery, what will decrease even further the oxygen supply to
the myocardium. On the other side, if tissue oxygen needs are not met, heart rate will rise
in  order  to increase cardiac  output,  what  may increase myocardial  oxigen  neads  and
potentially worsen the myocardial oxygen supply-demand mismatch. [145]
The meta-analisys  by  Liu  et  al [146] demonstrated  a  higher  risk  of  major  bleeding  in
anemic patients, that may also contribute to their poorer outcome. Bleeding is one of the
most  common  complications  of  ACS,  and  may  result  in  hypotension  and  in  a
hyperadrenergic state that may contribute to myocardial ischaemia by further decreasing
myocardial oxygen supply. [147]
Anemic patients are also more prone to have more associated co-morbidities and high risk
features,  as  observed in  our  results,  where anemic  patients  were older,  had a higher
prevalence of hypertension and DM and were more prone to have had a previous event,
what may also contribute to a worse outcome. The exceptions were their lower tendency
to have a family history of ACS and to be smokers. 
We also found a significantly higher concentration of initial troponin, Pro-BNP and CRP in
anemic patients, what may indicate a more severe ischaemic disease and a greater delay
in  treatment-seeking,  possibly due to, as previously mentioned, a higher prevalence of
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atypical symptoms or silent ischaemia. The higher concentration of CRP in anemic patients
is  particularly  interesting,  as  it  constitutes  an  indicator  of  a  more  marked  systemic
inflammation. This may be significant, as cytokines are known to inhibit erythropoietin
production, thus reducing reduced red blood cell production. [113]
The idea that anemic patients may have a more severe ischaemic disease and a greater
delay in  treatment-seeking  is also suported by the fact that these patients presented a
significantly  lower  LVEF  class,  what  may  indicate  a  greater  ischaemic  lesion.  Another
factor that may contribute to this  lower LVEF class is the greater incidence of previous
events, that may have already impaired LVEF, found in this patients.
The meta-analisys by Liu Y. et al. [146] also found that differences in therapeutic options
may also have a role in  the worse  prognosis of  patients with anaemia.  In the case of
anemic  patients,  doctors  often  prefer  a  more  conservative  approach  of  treatment,
possibly due to a higher prevalence of  contraindications to revascularization procedures
and to their higher risk of bleeding. Therefore, anemic patients are less likely to be treated
with aspirin and β-blockers and less likely to receive reperfusion therapy, that are known
to increase long-term survival and decrease the chances of ischaemic complications. This
was also comproved by our findings, where anemic patients,  in spite of having a greater
number of obstructed blood vessels, were significantly less likely to undergo PTCA. The
anemic patients  that  did  undergo  PTCA  presented,  however,  a  greater  number  of
revascularizated blood vessels than non-anemic patients.
As we have seen, anemia is associated with older age and with a higher prevalence of co-
morbidities and cardiovascular risk factors, what may contribute to the poorer prognosis
of  anemic patients.  However the adjusted hazard ratio for  hemoglobin concentrations
showed  that  the  increased  risk  of  lower  hemoglobin  concentrations  persisted  after
adjustment for  potential  confounders,  what  indicates that  an independent association
between anemia and mortality in patients with ACS.
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4.4 – PTCA
In spite of being associated with a higher risk of complications, especially bleeding, PTCA
is known to improve the outcome in patients with ACS, with various trials suggesting that
an invasive strategy of treatment normally leads to better outcomes than a conservative
strategy. [148] This improvement provided by PTCA in the outcome of patients with ACS
was not, however, verified in our study, as we found no significant effect of PTCA in death
or  in the probability of  occurrence of a posterior event.  A possible explanation for this
may be  the  fact  that  we  did  not  take  into  account  the  concomitant  pharmacological
therapy and the amount of time that passed until PTCA, what may also influence patient's
outcome, as current guidelines for the treatment of ACS recommend rapid PCI under the
protection of a platelet GP IIb/IIIa receptor antagonist. [148]
A study  by  Berger  et  al. [149] found that  30 day  mortality  was significantly  lower  in
patients that reveaved PTCA within 60 minutes and progressively higher in patients with a
greater delay.   That study found that the time from enrollment to first balloon inflation
was a significant predictor  of  30 day mortality  even after  adjustment  for  age,  systolic
blood pressure, baseline Killip class, smoking status, and diagnosis or treatment of cancer
in the last 5 years, with each time interval was associated with a 1.6 times (95% CI, 1.13 to
2.26;P =0.008) greater risk of death than the interval preceding it. 
Our results indicate that patients that underwent PTCA were younger, presented higher
hemoglobin concentrations  and a lower prevalence of  HTA and previous  events,  what
corroborates the fact that patients that are older, anemic or have a higher prevalence of
co-morbidities  and  cardiovascular  risk  factors tend  to  receive  a  more  conservative
treatment and are less prone to undergo PTCA, probably to their higher risk of bleeding. 
We also found that patients that were hospitalized due to STEMI were significantly more
prone to receive PTCA than the patients that were hospitalized due to  NSTEMI or UA,
what may constitute an indicator that STEMI is, in fact, associated with a higher degree of
blood vessel obstruction and, therefore, with a greater need for PTCA. This corroborate
the notion that UA and NSTEMI normally result from a partially occluded artery and STMI
from a fully occluded artery.
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Finally, patients that did undergo PTCA had a significantly higher number of obstructed
blood vessels, what may indicate that,  in patients with a higher number of obstructed
blood vessels, the  improvement in  the  outcome provided by PTCA supplants the  risk of
complications  and,  therefore,  doctors  more  commonly  submit  these  patients  to  this
revascularization procedure. 
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4.5 – LVEF
Our results indicate that a lower class of LVEF is associated with a higher  probability of
death or occurrence of a posterior event. This is not surprising,  as a lower LVEF is an
indicator of a greater ischaemic lesion and a lower  global  contractile function,  what is
associated with higher risk of cardiac arrest and arrhythmic death. 
The assumption that a lower LVEF class is an indicator of a greater ischaemic lesion is also
supported by the  differences found in the concentrations of  Initial troponin,  maximum
troponin, Pro-BNP and CRP found between the different classes of LVEF. 
Patients that had a lower LVEF class were older and more prone to anemia what may also
have  an  influence  in  their  worse  prognosis.  These  patients  also  presented  a  greater
incidence of previous events, what was also expected, as these previous events may have
resulted in myocardial lesion and in an already impaired global contractile function.
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4.6 – Hospitalization motive
Our results indicate that patients that were hospitalized due to UA were significantly less
prone to death than the patients that were hospitalized due to STEMI or NSTEMI, what
suggests that hospitalization motive has a significant impact in the probablitity of death.
We  did  not,  however,  find  a  significant  influence  of  hospitalization  motive  in  the
probability of occurrence of a posterior event. 
There  was  also  a  significant  difference  between  hospitalization  motives  in  the
concentrations of initial troponin, maximum troponin, and Pro-BNP, what was expected,
as  markers  of  myocardial  necrosis  and ischaemia  are  normally  elevated in  myocardial
infarction but not in UA.  A similar difference between hospitalization motives was also
found in the levels of CRP, what may be explained by the finds of Irfan et al, that observed
that  patients  with  UA  presented  presented  low-levels  of  CRP  when  compared  with
patients  hospitalized due to STEMI or NSTEMI. This suggests that CRP, besides being a
marker of inflammation, may also have an important role in plaque disruption leading to
STEMI and NSTEMI.
Patients that were hospitalized due to UA also presented a higher LVEF class and were less
less prone to anemia. The fact that that these patients presented a higher LVEF class is no
surprise,  as  UA  is not  commonly  associated  with  myocardial  necrosis  and,  therefore
presents a more preserved global contractile function. The lower prevalence of anemia in
these patients  may,  in part, be explained by their  lower  levels of CRP,  what indicates a
lower degree of systemic inflammation, that may, as previously mentioned, be responsible
for an impairment in red blood cell production.
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4.7 – Risk factors
4.7.1 – Family history of ACS
Our study found no significant association between the presence of a family history of ACS
and the probability of occurrence of a posterior event. Patients with a family history of
ACS were, however, less prone to death, what may be explained by their younger age and
by the lower prevalence of anemia in these patients.
These results indicate that, in spite of having an important role in the pathogenesis of ACS
and in making individuals more prone to  this  disease leading,  therefore, to  an earlier
onset,  genetic factors do not seem to  have an impact in the occurrence of a posterior
event.
4.7.2 – Previous event
We found a significant association between the presence of a previous event and a worse
outcome in patients with ACS, as these patients were more prone to death and had a
higher probability of occurrence of a posterior  event.  Survival  curves showed that the
type  of  previous  event  was  also  determinant  in  the  probability  of  occurrence  of  a
posterior event, as  patients that had a previous ACS presented a higher probability of
occurrence of a posterior event than the patients that had a previous stroke.
The worse outcome verified in patients with a previous event is not unexpected, as this
previous event may have already result in an important myocardial lesion.  We verified
that patients that had a previous event presented a lower LVEF class, what may indicate
that  the  previous  event  sustained  by  these  patients  may  have,  in  fact,  resulted in
significant myocardial  ischaemia and,  therefore, in an impairment of  global  contractile
function. Our results also indicate that the presence of a previous event is associated with
older age and a higher prevalence of anemia what may further contribute to a poorer
outcome.
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Finally,  the findings  by  Motivala et al.  [150] suggest  that  the  presence of  a  previous
myocardial  infarction  is  associated  with  a  higher  prevalence  of  co-morbidities  and
cardiovascular risk factors, but not with worse in-hospital outcomes during the recurrent
ACS episode, what indicates that clinical presentation has a greater  effect in in-hospital
outcomes than cardiovascular risk factors. 
4.7.3 – Hypertension
Several studies indicate that hypertension is the most important risk factor for an earlier
onset of stroke and is associated with an increased prevalence of adverse outcomes. This
was  also  evidenced  by  our  results as  the  survival  curves  obtained  indicate  that  the
presence of hypertension is associated with an increased probability of occurrence of a
posterior event. There was not, however, an association between hypertension and death.
[151], [152]
Patients  with  hypertension were  older  and  more  prone  to  be  female,  what  may  be
associated with an increased prevalence of co-morbidities and cardiovascular risk factors
what, in association with the higher prevalence of anemia in these patients, may also play
a role in their higher probability of having a posterior event. Finally, hypertensive patients
were less prone to receive PTCA, possibly due to a higher incidence of co-morbidies and
cardiovascular risk factors, what may also influence their risk of having a posterior event.
4.7.4 – Dyslipidemia
Our study found  a significant relationship between dyslipidemia  and a poorer outcome,
with a higher probability of death or occurrence of a posterior event, what may in part be
explaned by the findings of Kato et al. [153], that reported a relationship between higher
levels  of  LDL  and  lower  levels  of  HDL  and  a  higher  prevalence  of  multiple  complex
coronary  lesions  in  male  ACS  patients,  what  may  lead  to  an  increased  incidence  of
posterior events. 
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4.7.5 – Body mass index
We found  a  significant  relationship  betweem  a  BMI  greather  than  30  and  a  poorer
outcome, with a higher probability of death or occurrence of a posterior event. Various
studies have, however, reported better prognosis in overweight patients in a  so called
“obesity  paradox”.  Other  studies  have  reported  a  U-shaped  relationship,  with
underweight and obese patients presenting worse outcomes than overweight patients.
[154]
One possible explanation for this paradox Is that overweight patients are usually younger
and treated more aggressively,  what may  possibly contributing to improved outcomes.
Another hypothesis is that obese patients may present a larger coronary artery diameter.
It  is  however,  important to take into account  that BMI does not  allow the distinction
between muscle and fat mass and, therefore, certain overweight patients may have more
muscle mass. Certain researchers consider that this obesity paradox may disappear in the
cases where BMI is very high and better reflects body adiposity, what would also explain
why such paradox was not  found in our  trial,  as  we only differentiated obese and no
obese patients,  not distinguishing underweight normal weight and overweight patients.
[154], [155]
4.7.6 – Diabetes mellitus
Our  results  indicate  that  there  is no  significant  association  between  DM and  the
probability of occurrence of a posterior event. Patients with a family history of DM were,
however, more prone to death, what comes as no surprise, as it is well known that DM is
associated with an increase of 2-4 fold in the mortality rate. [152] Two important factors
that may have contributed to this higher mortality rate in the case of patients with DM
may be the older age and the lower prevalence of anemia in these patients. 
A study by  AlNemer et  al. [156] also found a  higher prevalence of  cardiovascular  risk
factor and co-morbidities in diabetic patients, what may also contribute to their worse
outcome.
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4.7.7 – Smoking
In spite of being a very important cardiovascular risk factor, various studies have reported
lower  mortality  rates  after  ACS  in  smokers,  what  may  indicate  a  protective  effect  of
smoking  that  would  make  smokers  more prone to  suffer  ACS  but  also  more likely  to
survive. [157]
Our  trial  presented  similar  results,  with  smokers  and  ex-smokers  having  a  lower
probability  of  death,  and  ex-smoker  having  a  lower  probability  of  occurrence  of  a
posterior event. It is however important to take into account that smokers and ex-smokers
were younger and more prone to be males, what suggests that they may present a lower
prevalence  of  cardiovascular  risk  factors  and  co-morbidities.  These patients  also
presented a lower prevalence of anemia and underwent PTCA more frequently, what may
also have contributed to a more favorable outcome. These assumptions are supported by
the findings of Gaspar et al. [157], that reported that patients with a history of tabagism
were younger, more frequently men, presented a lower prevalence of DM,  hypertension
and renal insufficiency and were more often referred for PTCA. 
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4.8 – Biomarkers
4.8.1 – Troponin
Cardiac troponins are widely used in the diagnosis and risk stratification of patients with
ACS. 
In our trial we found significantly higher initial troponin concentrations in older patients
and anemic patients. This supports the theory that a higher prevalence of co-morbidities
in  these  patients  may  make  them  more  prone  to  a  more  atypical  presentation  and
increased treatment-seeking delay, what would explain the higher initial levels of troponin
in these patients. 
Patients  that died also presented higher initial  troponin concentrations, what suggests
that this delay in treatment seeking is associated with poorer outcomes.  There was not,
however,  a  significant  influence  of  troponin  concentrations  in  the  probability  of
occurrence of a posterior event. 
It is particularly interesting to notice that we did not find a significant association between
maximum troponin  concentrations and death, what may be due to the fact that we did
not stratify troponin concentrations in terciles,  as in a study by  Knight et al. [158] the
upper tertile of cTnT (>1.1 mg/l) presented a significantly greater risk of death than that of
all the other troponin groups (p = 0,003).
We also found that patients with higher maximum troponin concentrations were more
prone  to  undergo  PTCA,  what  may  indicate  that  higher  troponin  concentrations  are
associated with a more severe blood vessel obstruction and, therefore, with a higher need
for PTCA.
Finally,  there  were  also  significant differences  in  the  maximum  levels  of  troponin
according  to  LVEF  class,  what  may  indicate  that  higher  troponin  concentrations  are
associated with a higher degree of myocardial necrosis and with a more compromised
global contractile capacity.  
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4.8.2 – Pro-BNP
Higher concentrations of  Pro-BNP presented a significant association with  an increased
probability  of  occurrence  of  a  posterior  event  and  the  patients  that  died  presented
significantly higher concentrations of Pro-BNP when compared to the patients that did not
die, what suggests that higher levels of Pro-BNP are associated with a worse outcome.
This  comes  as  no  surprise,  as  higher  levels  of  Pro-BNP are  indicative  of  more  severe
myocardial injury and greater cardiac dysfunction, what Is proved by the differences found
in Pro-BNP concentrations according to LVEF class.
It  is  important to notice that higher Pro-BNP concentrations were also found in older
patients, women and patients with anemia, what suggest that the higher prevalence of
cardiovascular  risk  factors  and  co-morbidities  characteristic  of  these  patients  may
contribute to a greater myocardial injury and cardiac dysfunction.
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5 – CONCLUSION
ACS is one of the most common initial manifestations of CVD, having reached pandemic
levels in developed countries. In the last couple of years there has been a reduction in the
mortality  rate  due  to  ischaemic  heart  disease,  specially  in  developed  countries,  but,
nonetheless, this disease is still responsible for approximately one third of all deaths in
persons older than 35 years of age. 
This is a multifactorial disease, with a complex  pathogenesis. However, in recent years,
there has been an evolution in the understanding of the molecular mechanisms involved
in ACS. This allowed the uncovering of various biomarkers that may be used in diagnosis
and in the evaluation of the extent of the myocardial damage. Also, various features are
know to be associated with an increased risk of development of ACS and with a worse
outcome and are, thus, taken into account in various risk scores. 
The evaluation of 980 patients with ACS hospitalized in CHBV  allowed the confirmation
that various factors are associated with an increased risk of a worse outcome in patients
with ACS, such as older age, female gender, presence of anemia, low LVEF, hypertension,
dyslipidemia,  obesity  and  the  presence  of  a  previous  event.  High  levels  of  specific
biomarkers were also associated with a worse outcome, particularly in the case of Pro-
BNP,  what  comes as  no  surprise,  as  they  are  indicative  of  greater  areas  of  ischaemic
lesion.  It  is  also important  to notice that  various  of  these features  also presented an
association with other risk factors and co-morbidities, what may render the determination
of their specific predictive value in ACS difficult. 
Risk assessment is very useful in patients with ACS, as patients at higher risk may need a
more aggressive approach of treatment and, therefore, risk scores should be used to help
the physician in determining the better treatment option. Patients with a higher risk of
worse outcome normally also have a greater risk of complications with the use of a more
aggressive treatment and, therefore, a risk/benefit evaluation should always be done.
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